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ABSTRACT OF DISSERTATION 
 
END-OF-LIFE DECISION-MAKING IN PATIENTS WITH A CARDIAC DEVICE 
 
Heart failure (HF) is one of the top causes of mortality in the United States and 
globally. In order to combat the high mortality rates of this disease, medical technology, 
including internal cardioverter defibrillators (ICD) and left ventricular assist devices 
(LVAD), have become one of the most common treatments. Over the past 10 years the 
utilization of these cardiac devices has increased exponentially, which has created a new 
phenomenon of how we discuss death with patients who have one of these devices. The 
purpose of this dissertation is to increase understanding of the end-of-life decision 
making processes and current experiences that patients with a cardiac device are having.  
This dissertation includes four original manuscripts that focus on patients with a 
cardiac device and their experiences with decision-making at the end-of-life. The first 
paper is a data-based paper that examines experiences of patients with an ICD and what 
factors are associated with having a conversation with their providers about end-of-life. 
The second paper is an integrative review of the literature regarding what is currently 
known about end-of-life with an LVAD. The third paper is a psychometric evaluation of 
the Control Attitudes Scale-Revised (CAS-R) for patients with an LVAD. The fourth 
paper is a data-based manuscript that looks at patients with an LVAD and their attitudes 
and experiences with end-of-life conversations with providers and next-of-kin and the 
impact of cognition on these attitudes and experiences. The findings of this dissertation 
will hopefully inform providers of patients with cardiac devices about their patients end-
of-life decision making processes. It will also demonstrate the gaps that are currently in 
practice, and ideally be able expand on how to assist patients and providers on improving 
communication about end-of-life decision making.  
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CHAPTER 1.  INTRODUCTION 
Heart disease continues to be the leading cause of death in the United States, 
accounting for 23% of all deaths, and killing more than 630,000 people in 2016.1 By the 
year 2030, it is estimated that 44% of American adults will have some type of 
cardiovascular disease.2 Cardiovascular disease is also the leading killer globally, 
estimated to have been the primary cause of death for over 17.3 million people in 2013.2 
One of the deadliest types of cardiovascular disease is cardiomyopathy, also referred to as 
heart failure (HF).  
In the United States, one in eight deaths is attributed to HF.3 In 2012, the total 
economic burden of HF was $30.7 billion, and by 2030 it is projected that this burden 
will increase by 127%.3 Despite these staggering statistics, there have been improvements 
in both 1-year and 5-year survival rates. This is primarily attributed to improvement in 
guideline-directed medical therapy.1 
 Several notable advances in HF medical therapy over the last decade have been 
linked to longer survival, including improved drug therapy, coronary revascularization 
therapies, and advanced medical devices, including implantable cardioverter defibrillators 
(ICD) and left ventricular assist devices (LVAD).4 Implantable cardioverter defibrillator 
and LVAD treatment are estimated to have saved hundreds of thousands of lives since 
their development.2  
 An ICD is a palm sized internal device that senses heart rhythms and can 
electrically convert an inappropriate rhythm to normal sinus rhythm. The primary 
indication for ICD therapy is to prevent sudden cardiac death in those who are high risk 
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for abnormal life-threatening rhythms, such as those with advanced heart failure, or after 
a myocardial infarction.5 Compared to optimized drug therapy, implantation of an ICD 
decreased mortality of sudden cardiac death by almost 30%.6 It is estimated that there are 
over 1.7 million Americans eligible for ICD treatment and over 12,000 lives are saved 
each year due to ICD therapy.7,8  
An LVAD is a mechanical pump that functions as the patient’s left ventricle. Left 
ventricular assist device therapy is targeted at patients with advanced heart failure, who 
have exhausted all other guideline-directed therapy and can either no longer wait for a 
heart transplant due to HF severity, or are not a candidate for heart transplantation. The 
first LVAD was developed in 1994 for in-hospital use only and had extremely high 
mortality rates.9 The device that is most similar to what we use today, the HeartMate II, 
was approved in the mid 2000’s with the well-known REMATCH trial.10 Data from this 
randomized clinical trial demonstrated that LVAD therapy was superior to optimized 
medical management for patients with advanced HF; LVAD therapy increased survival 
for patients and also demonstrated an improved quality of life.11 In the early post-
REMATCH era before 2009, there were less than 500 people with an LVAD. As of 2016, 
over 17,000 patients have received an LVAD.12,13  
 Although it is known that ICD and LVAD therapies save lives, it is inevitable that 
most of these patients will face death with the device in place. Implantable cardioverter 
defibrillator and LVAD devices, in the majority of cases, do not reverse HF or its effects 
on the human body, therefore, patients with these devices need information and guidance 
on how to incorporate their device into end-of-life planning.  
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Over the past several years professional organizations have developed guidance 
for communicating with patients who have an ICD or LVAD in relation to the end-of-
life. For providers of patients with an ICD, guidelines from the Heart Rhythm Society, in 
conjunction with other professional organizations, state that providers need to advise 
patients, prior to ICD implantation, about the potential for deactivation .14  For providers 
of patients with an LVAD, the Centers for Medicaid and Medicare Services mandate that 
a palliative care team must be involved in the care of LVAD patients, to ensure that goals 
of care are discussed, however, the guidelines are vague and do not explicitly state that 
deactivation of the LVAD or end-of-life be included in these discussions.15 Other 
professional organizations, such as the International Institute for Heart and Lung 
Transplantation, urge providers to incorporate end-of-life discussions into the care of 
patients with an LVAD, however, these guidelines are also vague and do not directly 
address deactivation or involvement of palliative care teams throughout LVAD therapy.16 
 Despite guidelines from professional organizations, patients with a cardiac device, 
their caregivers, and their health care providers do not seem to be equipped to deal with 
end-of-life situations that may arise with these devices. Results from numerous studies of 
patients with an ICD have shown that many experience inappropriate and unnecessary 
shocks toward the end-of-life, even within minutes before death.17-19 Even though 
professional guidelines urge providers of patients with an ICD to initiate discussions 
about ICD deactivation, researchers have demonstrated that these types of conversations 
happen infrequently, if at all, with patients and their families.19-21 These gaps in care can 
leave patients and their families in frustrating and confusing situations in a time that is 
already very difficult.  
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There has been very little research about end-of-life experiences or deactivation 
of the LVAD device. This is most likely related to the relative newness of the technology. 
Several editorials have been written regarding the lack of shared decision-making in the 
end-of-life processes associated with LVAD deactivation. These authors proposed that 
this problem may be related to a lack of understanding of the ethical permissibility of 
deactivation.22-25 In 3 qualitative studies examining LVAD patients and their caregivers, a 
common theme related to end-of-life with an LVAD emerged: confusion. The 
participants in these studies consistently voiced a lack of understanding of end-of-life 
processes with an LVAD, difficulty receiving information from providers about 
deactivation, and questions of whether it is ethical to turn the device off at all.26-28 
Providers of patients with LVADs also seem to have similar uncertainty about end-of-life 
with an LVAD. In a web-based survey of different specialties who take care of patients 
with LVADs, there were vastly different opinions regarding whether deactivation of the 
LVAD is considered active euthanasia or physician assisted suicide, as well as confusion 
how to integrate hospice and palliative medicine for patients who wish to deactivate their 
LVAD towards the end of their lives.29-31  
Therefore, the purpose of this dissertation was to examine patient attitudes and 
experiences related to end-of-life conversations involving their LVAD or ICD and factors 
involved in end-of-life decision making. The chapters of this dissertation demonstrate the 
development of my initial program of research. First, I did a secondary data analysis of a 
national cohort study of patients with an ICD to determine the factors associated with 
having a conversation about end-of-life with their providers. Second, I conducted an 
integrative review of the literature to examine what is currently known about end-of-life 
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with an LVAD related to providers’, patients’, and caregivers’ experiences of end-of-life 
with this device. Third, is an analysis of the psychometric properties of the Control 
Attitudes Scale-Revised in a population of patients with an LVAD. Last, I did an 
observational study of a cohort of patients with an LVAD and an exploration of their 
attitudes and experiences related to end-of-life decision-making and pump exchange of 
patients with an LVAD and the impact of cognition on these attitudes and experiences.  
1.1 Summary of Subsequent Chapters 
 In order to understand of predictors of end-of-life discussions and decision 
making in patients with an ICD, Chapter Two presents a secondary data analysis of a 
national cohort study comparing experiences, attitudes, and knowledge about the ICD at 
the end-of-life between ICD recipients with and without HF. A total of 3,067 ICD 
recipients participated, and 52% of the cohort had HF. End-of-life experiences, attitudes, 
and knowledge were measured using an end-of-life questionnaire, demographic and 
medical history information were self-reported, and information regarding ICD indication 
and shock history were gathered using a national Swedish ICD registry. Experiences, 
attitudes and knowledge were compared between the HF and non-HF groups and a 
logistic regression analysis was conducted to identify significant predictors of having a 
discussion with a health-care provider about end-of-life scenarios. The questionnaire and 
study design from this analysis were used to guide the study conducted and described in 
Chapter Five of this dissertation.  
For a more comprehensive understanding of what the LVAD population 
experiences towards the end-of-life, Chapter Three is an integrative review of the 
literature regarding processes and content of end-of-life discussions, and end-of-life 
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experiences of individuals, families, and health-care providers of patients with an LVAD. 
Several electronic databases were searched from earliest available through November 
2018, with keywords including ‘LVAD’ and ‘end-of-life’. Articles were included if they 
met the following criteria: were research studies that focused on the perspective about 
end-of-life of provider, caregiver, or patient with an LVAD, focused on adults 18 and 
older, and were published in English. Articles were excluded if the primary research 
focus was testing palliative care interventions in patients with an LVAD. Six articles met 
the inclusion criteria and were included in the integrative review. Three focused on 
provider knowledge and opinions of end-of-life for patients with an LVAD and three 
studies examined patient and caregiver experiences related to end-of-life processes 
associated with the LVAD.  
To ensure there is a validated instrument to measure perceived control, Chapter 
Four reports on the psychometric properties of the Control Attitudes Scale-Revise (CAS-
R) in an LVAD population. The CAS-R is a measure of perceived control, which is a 
variable that is often targeted in interventions to improve quality of life because of the 
ability to modify and improve perceived control. This was a secondary data analysis of 
89 LVAD patients from a larger prospective research study described elsewhere.32 The 
purpose of this study was to evaluate the internal consistency reliability and convergent 
validity of the CAS-R in an LVAD population. Reliability was assessed with Cronbach’s 
alpha, inter-item and item-total correlations to assess for homogeneity of the scale. 
Convergent validity was assessed using factor analysis and hypothesis testing.  
Last, in culmination of the research from the prior chapters, Chapter Five presents 
the findings of cross-sectional, correlational study of 30 patients with an LVAD focused 
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on end-of-life attitudes and experiences and the impact of cognition on those attitudes 
and experiences. Patients were eligible to participate if they had an LVAD device for the 
treatment of end-stage HF, had the device for at least 30 days, were able to complete a 
three-question cognitive assessment, and were able to speak and write English. 
Participants were excluded if they were less than 18 years of age or resided in an 
extended care nursing facility. Participants completed a cognitive screening tool and an 
end-of-life questionnaire focused on experiences related to end-of-life decision making 
and attitudes towards end-of-life decision making and pump exchanges.  
Chapter Six is an integrated discussion synthesizing the prior chapters of this 
dissertation and discusses how these studies contribute and advance what is already 
known regarding end-of-life decision making and care for patients with a cardiac device. 
There are also recommendations for future research and practice regarding end-of-life 
decision making in these populations.  
 
CHAPTER 2.  SHARED DECISION-MAKING ABOUT END-OF-LIFE CARE 
SCENARIOS COMPARED AMONG IMPLANTABLE CARDIOVERTER 
DEFIBRILLATOR PATIENTS WITH AND WITHOUT HEART FAILURE: A 
NATIONAL COHORT STUDY 
2.1 Introduction 
Heart failure (HF) affects over 6.5 million people in the US every year, and the 
trajectory of a patient’s life is shortened once a HF diagnosis has been made.1 Over 42% 
of people diagnosed with HF will die in less than five years after diagnosis.1 Many of 
these HF patients require the placement of an implantable cardioverter defibrillator (ICD) 
to prevent sudden cardiac death, a major cause of death in HF. There are about 800,000 
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patients with HF who have an ICD in the US, and an additional 800,000 HF patients who 
qualify for ICD treatment but do not have one.2  
Approximately 30% of ICD recipients experience a shock in the minutes before 
death.3 Many of these shocks are not in the context of sudden cardiac death, but in the 
context of death from a terminal illness such as cancer.4 According to guidelines 
developed by the Heart Rhythm Society, in conjunction with multiple professional 
organizations, providers are advised to discuss the potential for deactivation of ICDs in 
certain situations such as a terminal illness, prior to implantation of the ICD.5 Despite 
these guidelines, in multiple studies of patients with and without HF, these discussions 
did not occur, or occurred very infrequently.3,6,7 One of the consequences of failure to 
have end-of-life (EOL) discussions throughout the illness trajectory is potentially 
decreased quality of life (and quality of death experience) at the EOL. Thus, the purpose 
of this study was to compare experiences, attitudes and knowledge about the ICD at EOL 
between ICD recipients with and without HF to determine how well patients with HF 
could participate in EOL decisions. We hypothesized that given the poor prognosis in HF 
compared to other patients with an ICD, clinicians would have had discussions about the 
ICD at the EOL with HF patients more commonly. 
2.2 Methods 
2.2.1 Sample, Study Design, and Data Collection 
 This study was a cross-sectional and correlational design. All data were self-
reported and participants were recruited from the national database of all Swedish ICD 
and pacemaker recipients. This registry has been active since 1989 and included 5,535 
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adult ICD recipients as of 2012. All ICD recipients were sent an invitation to participate 
in the study, and if a signed consent form was returned, a questionnaire was mailed. If the 
questionnaire was not returned in two weeks, one reminder was sent out. This study was 
sanctioned by the Regional Ethics Committee for Human Research at the University of 
Linköping, Sweden and followed the principles outlined by the Declaration of Helsinki.  
2.2.2 Demographic and Clinical data 
 Demographic data and information on participants’ co-morbidities, including HF, 
medications, and ICD shock history were collected using self-report. Data regarding 
indications for ICD placement, implantation and generator replacement history, and 
device types (ICD versus ICD with a cardiac resynchronization pacemaker/CRT-D) were 
collected using the Swedish ICD and Pacemaker Registry.  
2.2.3 End-of-life information 
 The questionnaire used to collect data on EOL knowledge, perceptions, and 
attitudes is titled “Experiences, Attitudes, and Knowledge of End-of-Life Issues in ICD 
Patients” (EOL-ICD). It is a self-rated questionnaire that includes three domains related 
to EOL in patients with an ICD. The domains included are, experiences (10 items), 
attitudes (18 items), and knowledge (11 items). This questionnaire was developed and 
tested for construct validity, content, homogeneity and reliability in a Swedish setting; 
these properties were considered sufficient after evaluation.8 In the current sample of 
2,566 participants with an ICD the Cronbach’s alpha was 0.719.  
 The experience domain included items about discussions with either providers or 
family about EOL care and experiences. An example of an item in this domain was, “I 
 10 
have told my next of kin (either in writing or orally) my wishes regarding the defibrillator 
shocks in my ICD, if I become seriously ill with some fatal disease”. The knowledge 
domain was concerned with the patient knowledge about ICD deactivation. An example 
of a question in this domain was, “An ICD always gives defibrillator shocks in 
connection with end-of-life”. Lastly, the attitudes domain included items about the 
patient’s feelings, emotions, and attitudes about potential discussions related to ICD 
deactivation and future events related to the ICD. An example in this domain was “I want 
to have the defibrillator shocks in my ICD even if I’m dying of cancer or another serious 
disease”. Patients listed their answers to these questions as “agree/don’t agree”, 
“true/false”, “I don’t know”, “yes/no”, or “no opinion”.  
2.2.4 Implantable Cardioverter Defibrillator Concerns Scale  
 The Internal Defibrillator Concerns Scale (ICDC) short version is an 8-item scale 
that assesses patient related concerns regarding the ICD. This instrument helps identify 
patients who are at risk for adverse outcomes related to the ICD by identifying how 
worried various aspects related to the ICD the patient is concerned with.9,10 Patients rate 
the items on a 5-point Likert scale with 0 being not worried at all, to 4 being very much 
worried.10 The items are scored and totaled with a range from 0-32, with 0 being not 
worried at all about the ICD, to 32 being extremely concerned about the ICD.10 This has 
been shown to have excellent reliability and validity in various ICD populations.9,10 In the 
current sample of 3,003 participants with an ICD, the Cronbach’s alpha was 0.944, also 
indicating excellent reliability. The median total score from the sample was used as a cut-
point for low ICD concerns, and higher ICD level of concerns. 
2.2.5 Hospital Anxiety and Depression Scale  
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 The Hospital Anxiety and Depression Scale (HADS) is a brief self-report 
instrument used to detect symptoms of anxiety and depression in multiple 
populations..11,12 It is divided into anxiety and depressive subscales that have also been 
validated and have demonstrated good reliability.11,13 The anxiety and depression 
subscales each have 7 items, scored on a 4-point Likert scale; each item score on the 
subscale are summed and can have a total score from 0-21.11 Based on clinical 
presentations of generalized anxiety and depressive disorders, cut points of greater than 
or equal to 8 on the HADS anxiety and depression subscales were considered acceptable 
cut-points.11  
2.2.6 Data analysis 
 For data analysis, we used SPSS version 24. We used means ± standard 
deviations, and frequencies and proportions to describe patient characteristics. 
Comparison of demographic and clinical characteristics, and experiences, attitudes, and 
knowledge between HF and non-HF groups was accomplished using X2 and independent 
t-tests. Hierarchal binary logistic regression was used to determine predictors of whether 
or not participants had deactivation discussions with their providers. The assumptions for 
logistic regression were tested and were not violated. The outcome was participant 
responses to the question “Have you discussed what turning off shocks/deactivating the 
ICD involves with a doctor?” Four blocks were entered, in block one sociodemographic 
information was entered, block two included co-morbidities, block three included ICD 
related information, and block four was anxiety and depression. A probability values of 
less than 0.05 was considered to be statistically significant.  
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2.3 Results 
2.3.1 Sample Characteristics 
 There was a total of 3,067 participants who responded to the questionnaire and 
were included in the analysis (Table 2.1). Of these, 1,461 (47%) stated they had HF. The 
average age of the participants with HF were older than those without HF (p-value 
<0.001). The HF cohort was more likely to have higher levels of depressive and anxiety 
symptoms compared with the non-HF (p-value <0.001). The HF cohort was more likely 
to suffer from comorbidities including history of myocardial infarction, diabetes and 
history of stroke (p-values all less than 0.001). It was also evident that those participants 
without HF were more likely to have experienced a shock than those with HF (p-value 
0.012), and those without HF were more likely to have received an ICD related to 
secondary prevention compared to those with HF (p-value <0.001). See Table 2.1.  
2.3.2 EOL-ICDQ Results 
 To determine whether there were differences in understanding of EOL situations 
between those with and without HF, we compared responses to the EOL-ICD 
questionnaire between HF and non-HF cohorts (Table 2.2). There was little variation 
between the cohorts in the majority of the domains indicating that in general, they had the 
same attitudes and equivalent knowledge about ICD deactivation, EOL care, and patient 
control. However, some differences were observed between the cohorts in the 
experiences domain (Table 2.2). Those without HF were more likely to have discussed 
battery replacement with their provider and next-of-kin than those with HF. Additionally, 
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a larger percentage of those without HF had more thoughts and questions concerning 
EOL compared to those with HF.  
 Tables 2.3A and 2.3B show the results of the attitudes portion of the EOL-ICDQ. 
Among these 18 questions, there were only significant differences between cohorts for 
two questions. Question 13, would you want the ICD battery replaced, even at an 
advanced age. A higher percentage of patients with HF replied “yes” than those without 
HF. The other difference in the attitudes portion of the questionnaire was regarding the 
desire for the doctor to decide if ICD shocks should be turned off at the EOL. More 
patients with HF replied “yes” they would prefer this option compared to those without 
HF.  
 Last, in Table 2.4, the percentage of each cohort that got the questions correct, as 
well as the total knowledge score of the EOL-ICDQ are presented. While there was no 
difference in the overall scores between the cohorts, there were three questions that the 
non-HF cohort picked the correct response more than the HF cohort. Question 12 was the 
only question that the HF cohort picked the correct response more frequently that the 
non-HF cohort.  
2.3.3 Hierarchal Logistic Regression Results  
 Because we found that HF was not related to more comprehensive understanding 
of EOL with an ICD, we sought to understand what predictors were associated with 
having discussions with providers regarding EOL with an ICD. To determine these 
predictors a hierarchal logistic regression was performed. Block one with age, gender, 
education, and living alone was non-significant. Block two was significant with HF, atrial 
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fibrillation, and history of myocardial infarction were entered in the model (p =0.003); 
the Hosmer and Lemeshow goodness-of-fit coefficient was 0.296, indicating acceptable 
model fit. In block three, ICD variables were entered, including whether patients had a 
high level of ICD concerns, whether they had been shocked in the past, and whether their 
ICD was implanted for secondary prevention. This model block had a p-value of less than 
0.001 and the Hosmer and Lemeshow test showed a coefficient of 0.601, indicating good 
model fit. In block four, whether or not patients had symptoms of anxiety and depression 
were added to the model. The model remained significant with highest Hosmer and 
Lemeshow coefficient of 0.958, indicating good model fit. In the final model with all 
potential predictors, the significant predictors of having a discussion with the provider 
were having high levels of ICD concerns (p<0.01), having had a shock in the past 
(p<0.001), and having a high level of anxiety (p=0.027; Table 2.5).  
2.4 Discussion 
 Our hypothesis that participants with HF would have a better understanding of 
EOL with an ICD because of their shortened life expectancy was not supported.1 Results 
from the EOL-ICDQ indicated that participants with and without HF had similar 
responses. However, we also saw that the participants with HF had more symptoms of 
anxiety and depression compared to those without. Despite the shortened life expectancy, 
and higher levels of symptoms of anxiety and depression, those with HF did not want to 
initiate discussions regarding EOL any more frequently than those without.  
 Our results are congruent with other research in the ICD and HF communities. It 
has been shown that patients are reluctant to have their ICD deactivated at the  EOL, 
despite recommendations from providers.14-16 It is also uncommon to have information 
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regarding ICD deactivation in an advanced directive or living will.17 This is consistent 
with our findings which demonstrate that over 40% state they never wanted to have a 
discussion about deactivation of the ICD at the EOL with their provider, and only 11% of 
those with HF had ever had any EOL conversation with their next-of-kin. It also 
important to note that both those with and without HF had poor knowledge regarding 
what EOL with an ICD entailed. In the same cohort of Swedish participants, only 3% of 
participants scored correctly on all the knowledge questions and over 25% were 
considered to have inadequate knowledge.18 This prior study also demonstrated that those 
with poor knowledge were more likely to have a stressful and potentially painful EOL.18 
Poor knowledge and lack of desire to have a discussion regarding EOL with an ICD are 
strong barriers to shared decision making regarding the EOL.  
 Shared decision making, an established concept, is becoming a more crucial 
component of modern healthcare. This concept is succinctly described as “helping 
patients understand the importance of their values and preferences in making decisions 
that are the best for them”.19 It is ideally used in individualizing the plan of care for 
patients and ensuring that they are receiving medical treatment that is cohesive with 
patients’ goals for life, or in our scenario, the goals for EOL care. Initially we 
hypothesized that those with HF would have a higher level of shared decision making 
because of their shortened life expectancy and complications of their chronic disease, 
however, through our analysis we saw that in general, their experiences and preferences 
were identical to those without HF.  
We found factors associated with having a deactivation discussion were primarily 
ICD related, including a history of an ICD shock and having high levels of ICD concerns. 
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The other factor was anxiety symptom, which has a significant relationship with shared 
decision making and how patients interact with their providers.20 These associations may 
indicate when there is a potential for interventions regarding education on EOL scenarios. 
If we know patients are more open to having conversations about EOL after they have 
been shocked, or have high levels of anxiety and concerns about their ICD, we can 
prompt these types of discussions and ideally increase patients’ awareness about how an 
ICD can impact EOL. In a recent systematic review of the literature, a key point of shared 
decision making revolved around whether a patient is willing to take action.21 In this 
sample we saw that when patients had received an ICD shock, or when they had levels of 
concern about their ICD, they were more willing to take action regarding creating a plan 
for their EOL that included their ICD.  
 By having a more thorough understanding of which patients are willing to 
participate in EOL education, we may be able to address misconceptions and improve 
quality of death in this population. Having a HF diagnosis may not be sufficient to 
overcome the barrier of not wanting to discuss EOL with providers, but other clinical 
scenarios, such as being shocked or having high levels of symptoms of anxiety, do 
provide this kind of opportunity, and as providers it is crucial to capture them at these 
times. Additionally, shared-decision making regarding EOL can help alleviate some of 
the problems that frequently occur at the end of life, such as being shocked 
inappropriately, or forcing the next-of-kin to make a decision about deactivation when 
they have never had this type of discussion with their loved one. 
 Moving forward it will be important to understand how to educate patients with 
HF about EOL scenarios with an ICD. Despite the guidelines that suggest providers have 
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these discussions prior to implantation and regularly after implant, our study shows that 
this ongoing discussion did not occur in the majority of participants. Additional studies 
should focus on ways to reach patients with and without HF who are reluctant to discuss 
EOL scenarios with providers ever, because we saw this was almost half of our sample. 
These patients may need additional education prior to implantation to ensure they 
understand the implications that cardiac devices may place on their lives and their deaths, 
and make sure the care team understands their wishes.  
2.5 Limitations 
 There were several limitations to this study, including that all the respondents 
were from the same geographical location, which limits generalizability. Also, because 
this information was self-reported through survey, some portions of the population may 
not have been able to respond, also limiting generalizability.  
2.6 Conclusions 
 While HF diagnosis was not associated with increased likelihood of having 
discussions about EOL with a provider, several other factors were identified, including 
high ICD concern level, high levels of symptoms of anxiety, and having an ICD shock. 
Future studies should focus on ways to better reach patients who are reluctant to have 
discussions regarding EOL. More education and guidance is also needed for providers 
regarding having discussions about EOL with patients an ICD to better improve patient 
quality of life and quality of death.   
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Table 2.1. Patient Characteristics and Comparison of Characteristics by Heart Failure and 
Non-Heart Failure Status (N=3067) 
 Total 
N=3067 








Sociodemographics Mean ± SD or n (%) 
Age 66 ± 12 67 0.101 10 64 ± 13 <0.001 
Female 629 (21) 309 (19) 320 (22) 0.073 
Living Alone 648 (21) 352 (22) 296 (20) 0.240 
Education: 9 years or less 1009 (33) 533 (34) 476 (33) 0.700 
Works outside the home 705 (23) 280 (18) 425 (30) <0.001 
Pensioner 2074 (68) 1162 (76) 912 (65) <0.001 
Other Employment Type 156 (5) 91 (6) 65 (5) <0.001 
Time since implant: years  5 ± 4 4 ± 4 5 ± 4 <0.001 
CRT-D 2346 (77) 578 (36) 139 (10) <0.001 
Etiology: cardiomyopathies 2428 (79) 1422 (90) 1006 (70) <0.001 
Myocardial Infarction 1037 (34) 677 (42) 360 (25) <0.001 
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Diabetes 612 (20) 376 (23) 236 (16) <0.001 
Hypertension 1072 (35) 581 (36) 491 (34) 0.139 
Stroke 272 (9) 186 (12) 86 (6) <0.001 
Depression: >HADS 8 263 (9) 173 (11) 90 (6) <0.001 
Anxiety: >HADS 8 485 (16) 299 (19) 186 (13) <0.001 
Has received a shock 1056 (35) 519 (33) 537 (37) 0.012 
Received ICD for secondary 
prevention  
1957 (64) 828(52) 1129(77) <0.001 
Legend: CRT-D- Cardiac resynchronization therapy-defibrillator; HADS- Hospital anxiety 
and depression scale  
 
Table 2.2: Comparison of Implantable Cardioverter Defibrillator Experiences Between 










Question 1: Discussed Battery 
Replacement with Doctor/Nurse, Yes 
636 (40) 674 (47) <0.001 
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Question 2: Discussed battery 
replacement with next-of-kin, Yes 
468 (29) 518 (36) <0.001 
Question 3: Discussed what turning off 
shocks with a doctor involves, Yes  
216 (14) 222 (15) 0.148 
Question 4: Discussed what turning off 
shocks means with next-of-kin, Yes 
171 (11) 163 (11) 0.642 
Question 5: Informed next-of-kin 
wishes related to defibrillator shocks if 
seriously ill, Yes  
123 (8) 86 (6) 0.062 
Question 6: Considered asking doctor 
to turn off shocks, Yes 
46 (3) 71 (5) 0.004 
Question 7: Discussed heart disease 
development with doctor  
624 (39) 502 (35) 0.014 
Question 8: Discussed heart disease 
development with next-of-kin 
665 (42) 470 (33) <0.001 
Question 9: Has a religious 
faith/outlook on life, helps manage 
daily life, Yes  
1317 (83) 1209 (84) 0.403 
Question 10: Often think about 
questions concerning End-of-life, Yes 
1296 (82) 1233 (86) 0.003 
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Table 2.3A: Implantable Cardioverter Defibrillator Attitudes 
When would you like healthcare staff to broach the question of what it involves to turn 
off the defibrillation shocks in your ICD – Heart Failure vs. Non-Heart Failure 








Question 1: Pt does not wish to 
have such conversation, Agree 
633 (40) 571 (40) 0.911 
Question 2: Pt will themselves 
broach the question when they 
feel they need to, Agree  
1326 (84) 1203 (84) 1.000 
Question 3: In connection with 
ICD surgery, Agree 
759 (49) 707 (51) 0.377 
Question 4: If pt receives a 
defibrillator shock, Agree 
815 (52) 687 (49) 0.091 
Question 5: If pt has repeated 
defibrillator shocks, Agree 
1022 (66) 916 (65) 0.644 
Question 6: Upon repeatedly 
being hospitalized because of 
981 (63) 889 (63) 1.000 
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recurring heart problems, 
Agree 
Question 7: If pt should suffer 
from disease with poor 
prognosis, Agree 
1007 (64) 925 (65) 0.619 
Question 8: Routinely when pt 
visits the ICD clinic 
670 (43) 579 (41) 0.354 
Question 9: If heart disease 
deteriorates, Agree 
1015 (65) 920 (65) 0.818 
Question 10: Towards end-of-
life, during last days, Agree 
1077 (69) 966 (69) 0.691 
Legend: Pt- patient; ICD- Implantable cardioverter defibrillator 
 
Table 2.3B: Implantable Cardioverter Defibrillator Attitudes 
“In time your general state of health or heart disease may deteriorate. Try to imagine 
how you (the patient), at this moment, feel about your (the patient) ICD treatment in 
the future…” 








Question 11: Pt wants to have the 
battery in ICD replaced even if they 
never received defibrillator shocks: 
     Yes 
     No 



















Question 12: PT wants to have battery 
replaced, even if seriously ill suffering 
from another disease: 
     Yes 
     No 

















Question 13: Pt wants to have battery 
replaced even if reached an advanced 
age: 













     No 
     No opinion  
410 (26) 405 (28) 
Question 14: Pt wants to have 
defibrillator shocks even if pt dying of 
cancer or other serious disease: 
     Yes 
     No 

















Question 15: Pt wants to have 
defibrillator shocks even if receiving 
shocks daily:  
     Yes 
     No 














Question 16: Pt wishes to decide 
themselves if shocks are to be turned 
off when finding themselves at end-of-
life 














     No 





Question 17: Pt wants the doctor to 
decide if the shocks be turned off at the 
end-of-life: 
     Yes 
     No 

















Question 18: Pt wants next-of-kin to 
decide if the shocks be turned off when 
pt at the end-of-life:  
     Yes 
     No 


















Table 2.4: Implantable Cardioverter Defibrillator (ICD) Knowledge Questions 
Each statement had a correct answer, participants could choose either true or false 
based on their own knowledge about their ICD. 
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Question 1: Correct  1161 (74) 1100 (77) 0.038 
Question 2: Correct  1074 (68) 1036 (73) 0.009 
Question 3: Correct 1326 (84) 1224 (86) 0.218 
Question 4: Correct  982 (63) 914 (64) 0.343 
Question 5: Correct  1147 (73) 1051 (74) 0.508 
Question 7: Correct  671 (43) 600 (42) 0.795 
Question 8: Correct  1107 (70) 990 (70) 0.689 
Question 9: Correct  570 (36) 587 (41) 0.005 
Question 10: Correct  451 (29) 433 (31) 0.316 
Question 11: Correct 1015 (65) 941 (66) 0.420 
Question 12: Correct  774 (49) 632 (44) 0.007 
Total Score (mean ± 
SD) 
6.6±2.7 6.7±2.8 0.251 
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Table 2.5: Independent predictors of having an end-of-life discussion with a provider; N= 
2,840 
 Odds Ratio 95% Confidence 
Interval 
B SE P 
Age 0.994 0.984-1.003 -0.006 0.005 0.200 
Gender: Female 1.056 0.808-1.380 0.054 0.137 0.691 
Living Alone 1.079 0.832-1.398 0.076 0.132 0.567 
More than 9 
years of 
education 
0.893 0.705-1.131 -0.113 0.120 0.347 
Has heart 
failure 
0.895 0.712-1.127 -0.111 0.117 0.346 
Has atrial 
fibrillation  
1.206 0.962-1.512 0.187 0.115 0.104 
History of MI 0.797 0.625-1.016 -0.227 0.124 0.067 
High Level of 
ICD concerns 
(score on ICDC 
>7) 
1.526 1.217-1.915 0.423 0.116 <0.001 
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Having had an 
ICD shock in 
the past 














1.038 0.701-1.537 0.038 0.200 0.851 
Legend: Overall model p-value <0.001; ICD: internal cardioverter defibrillator; ICDC: 
internal cardioverter defibrillator concerns scale; HADS: hospital anxiety and depression 




CHAPTER 3. LEFT VENTRICULAR ASSIST DEVICES AT THE END-OF-LIFE: AN 
INTEGRATIVE REVIEW 
3.1 Introduction 
 Heart failure (HF) is a growing epidemic in the United States. By the year 2030 
over 8 million Americans will have a HF diagnosis.1 Despite the increasing prevalence of 
the condition, and improved guideline directed medical therapy, the five-year mortality 
rate of HF is still extremely high at 80%. 2 Since the Food and Drug Administration first 
approved left ventricular assist devices (LVADs) for use as bridge to heart transplantation 
in 1994, the science and rapid utilization of these devices has grown exponentially.3 
Between 2008 and 2016, over 17,000 LVADs were implanted in the United States and 
that number will continue to grow due to the lack of available donor hearts and the 
growing number of Americans with HF.4 While scientific advancements such as LVADs 
do increase life expectancy compared to optimized medical management, the mortality 
rate at one year is 19%.4,5 While many patients experience improvements in their quality 
of life after implantation, around 20% of LVAD patients experience a poorer quality of 
life post-implant.6  
Despite the life-prolonging capacity of LVADs, there are significant risks 
associated with the device that can ultimately lead to death. The most common causes of 
death in the LVAD population are neurologic complications, primarily stroke, which is 
the primary cause of death in 20% of patients. Multi-system organ failure is responsible 
for death in 14% of LVAD patients, and major infection is the cause of death in 7.6% of 
patients.7 Investigators have also demonstrated that compared to other chronic illnesses, 




comfort of their own home or other location of their choice.8,9 Because of these factors, it 
is critical that patients who have been implanted with an LVAD, their healthcare 
providers, and their next-of-kin discuss end-of-life situations and are prepared for when 
the inevitable occurs.  
Professional organizations that advise providers who care for patients with an 
LVAD have acknowledged that end-of-life is an important area and have created 
guidelines for providers. The Centers for Medicaid and Medicare Services have mandated 
that a palliative care team be involved in the care of LVAD patients to ensure that goals 
of care be discussed, but these guidelines are vague and do not discuss the extent to 
which palliative care must be involved, the composition of the palliative care team, or if 
end-of-life discussions must occur.10 The International Society for Heart and Lung 
Transplantation also recommends that a palliative care team be involved prior to LVAD 
implantation to help facilitate discussion of end-of-life and establish an advanced 
directive; however, there is no recommendation about the continuation of palliative care 
involvement, or what content should be discussed in these consultations other than 
advanced directives.11  
 Authors of several editorials have also discussed end-of-life with an LVAD and 
determined that there is a strong need for increased shared decision-making among 
LVAD patients, caregivers, and their providers.12,13 These experts proposed that a lack of 
shared-decision-making has created confusion for patients, families, and clinicians 
involved in end-of-life discussions.12,13  Phan et al., discussed how death can be hard to 
determine in patients with an LVAD due to the technical aspects of the device, which can 




cause extreme confusion and frustration, especially for families who are often deemed the 
decision-maker at the EOL.14 In an attempt to deliver a consensus on the ethical 
permissibility of LVAD deactivation, Rady and Verheijide evaluated the legality of 
deactivation. They determined after consultation with physicians and legal 
representatives, that in a new onset lethal condition only, such as new diagnosis of 
cancer, it is ethically permissible to deactivate an LVAD.15 
High mortality rates, vague guidelines about end-of-life care, and a demand of 
further understanding by providers seen in published editorials, clearly demonstrate a 
need for a more thorough understanding about end-of-life care for patients with an 
LVAD. Despite a few pilot studies that examined the effectiveness of preparedness 
planning for dyads including patients with an LVAD and their caregivers,16-18 there is no 
established understanding of end-of-life decision making in the literature. This includes 
understanding current practice with the various participants in the LVAD community 
including providers/clinicians, caregivers, and patients with an LVAD. Therefore, the 
purpose of this integrative review was to systematically evaluate research studies that 
focused on the process and content of end-of-life discussions, attitudes towards these 
discussions, and end-of-life experiences of individuals, families, and health care 
providers of patients with an LVAD.  
3.2 Methods 
3.2.1 Search Strategies 
 We performed a literature search of the PubMed, PsychINFO, and CINAHL 




and “end of life”. Secondary search terms utilized were “provider”, “caregiver”, 
“physician”, and “coordinator”. Databases were searched from earliest available to 
November 1st, 2018; no time restriction was used as the use of the LVAD is a recent 
innovation. References from the thirteen articles selected for full analysis for inclusion 
were evaluated, but revealed no new studies for review.  
3.2.2 Inclusion and Exclusion Criteria 
 Studies were included in this review when they: 1) were research studies that 
focused on the perspective about end-of-life of provider, caregiver, or patient with an 
LVAD 2) focused on adults (³18 or older); and 3) were published in English. Articles 
were excluded when the primary research focus was testing palliative care interventions 
for preparedness planning.   
3.2.3 Quality Assessment  
 Multiple study designs were included in this integrative review; thus, an 
instrument designed to assess multiple types of studies was needed. Pluye et al,19 
developed an instrument that incorporates multiple types of assessments for the various 
study types, including mixed-methods, quantitative, and qualitative studies. This 
instrument is known as the Mixed Methods Appraisal Tool (MMAT), version 2018.20 The 
MMAT has two screening questions that apply to each type of study, and then depending 
on the specific study type, there is a range of 3-5 items appraising the quality of the 
various studies. The developers of this instrument suggest not scoring the quality, but 
rather assessing whether each study has addressed the various appraisal items with an 




The authors then suggest judging over-all quality by reviewing the explanations of the 
criterion and comparing results of the common studies to make an over-all conclusion.20   
3.3 Results 
 The initial search strategy resulted in 68 articles, and after abstract review and 
application of inclusion and exclusion criteria, 13 studies were evaluated for full review 
(see Figure 3.1 for flow-chart). After full review, six studies were included in the 
integrative review based on inclusion and exclusion criteria. Three were qualitative 
studies focused on end-of-life discussions and experiences of caregivers and patients with 
an LVAD, two quantitative studies focused on provider opinions about LVAD 
deactivation or withdrawal of an LVAD, and one mixed-methods study focused on 
provider opinions of LVAD withdrawal and deactivation. 
 The qualitative studies included in this review used grounded theory and 
qualitative descriptive methodology. Investigators for all studies used convenience 
sampling, and for two out of the three, investigators used open-ended, semi-structured 
interviews;21,22 researchers for the remaining study used a structured, three-question open-
ended interview style.23 All interviews focused on patients and caregivers experiences 
with end-of-life discussions, or the experiences of caregivers related to the processes 
associated with end-of-life with an LVAD. The qualitative studies included in this review 
had a total of 70 caregivers and 39 patients with an LVAD. The caregivers in these 
studies were predominantly female, white, and either married or cohabitating partners of 
patients with an LVAD. The 39 patients with an LVAD interviewed in these qualitative 
analyses were predominantly white, males, and over 50 years of age; this is consistent 




Investigators for the two quantitative studies and the mixed-methods study, used 
cross-sectional designs. The investigators for the two quantitative studies, and the mixed-
method study all used a 41-item web-based survey entitled, “Characterization of 
Physician Attitudes Towards Deactivation of Left Ventricular Assist Devices as 
Destination Therapy at Life’s End”, which focused on attitudes and practices of clinicians 
who cared for patients with an LVAD at the end-of-life. In addition to the web-based 
survey, investigators for the mixed-methods study used a convergent parallel study 
design, indicating that the researchers collected the quantitative and qualitative data at the 
same time, where they asked the participants to elaborate on why they chose certain 
answers.24 In all three studies, a total of 865 clinicians who provided care to patients with 
an LVAD completed the web-based survey, most were physicians, male, and in the 
cardiology field.24-26 
3.3.1 Qualitative Studies about End-of-Life 
 The qualitative evaluation of patient and caregiver end-of-life experiences or 
discussions were examined in three studies,21-23 with similar themes emerging in all. 
Caregivers of patients with an LVAD were interviewed in all three studies; however, in 
one study caregivers as well as patients were interviewed.22 Investigators for only one of 
the studies recruited participants at multiple institutions,22 while investigators for the 
other two studies recruited participants from a single institution.21,23  
  3.3.1.1 Difficulty Receiving Information 
 The most common theme identified by investigators in all three qualitative 




receiving information from healthcare providers about the end-of-life experience. One 
participant stated, “In fact, I did ask them one time and I didn’t get an answer…” 
regarding what the end-of-life with an LVAD would be like.22 There was a strong desire 
from caregivers to understand what would occur at the end-of-life, and unfortunately 
many providers, especially those with hospice and palliative care, could not answer their 
questions, because the providers lacked the knowledge to respond.21,23  The inability of 
providers to inform patients and their caregivers about what happens at the end-of-life led 
to confusion and frustration for patients and their caregivers about end-of-life 
experiences. Thus, investigators concluded that patients had difficulty getting the 
information because providers did not have adequate knowledge or experience to be able 
to answer their questions. The statement below is an example of this theme: 
“They don’t know what they’re gonna do... Do you leave the mechanism running 
or do you turn it off? They don’t know.”22 
  3.3.1.2 Processes of End-of-Life with an LVAD  
Another common theme identified by investigators for all three studies was a 
desire by patients and caregivers to understand how an LVAD would affect the process of 
end-of-life. A number of caregivers discussed the need for a detailed plan that described 
how the pump would be turned off when the end-of-life was near.23 Caregivers also 
expressed confusion about whether death could even occur with the LVAD in place.21 
This lack of understanding by the patients and the caregivers regarding what end-of-life 
would be like was central throughout the qualitative interviews, and was compounded by 
the lack of answers from providers. Investigators from all three studies concluded that 




of-life and deactivation of the device once the time comes close. Below is an example of 
caregiver quote related to this theme: 
“But it just seemed that the rug got pulled out from under us. And we kinda didn’t 
understand what was going on, and to what extent it all meant.”21 
Patients and caregivers also expressed frustration related to the integration of 
hospice and palliative care resources during the end-of-life processes. Some patients and 
families felt like they were abandoned by their LVAD team when they were transferred 
to hospice team, and wanted their primary LVAD team to guide them through the end-of-
life, rather than a team full of strangers.23 Caregivers in a different study also voiced a 
similar concern; they felt that the hospice and palliative care teams did not know how to 
take care of the LVAD, and therefore did not feel comfortable taking care of the patient.21 
They also voiced that when they had to call emergency personnel because their loved one 
with an LVAD had collapsed, the emergency personnel had to no idea how to take care 
of the patient and the caregiver was too upset to try to explain what to do to help.21 These 
interactions with other teams, outside the LVAD team, demonstrate a lack of education of 
other personnel who may come into contact with LVAD patients and their families 
during the emotional time of end-of-life, and the detrimental effects it can have.  
3.3.1.3 Ethical Issues of Deactivation of the LVAD 
A third common theme focused on the ethical issues associated with the 
appropriateness of deactivation of the LVAD at the end-of-life. McIlvennan et al. found 
that six of the eight caregivers viewed deactivation of the LVAD as suicide, and one 




This question of ethical permissibility of deactivation can negatively affect patients’ and 
caregivers’ decisions at end-of-life and make it much more difficult for them to make a 
decision.  
3.3.2 Provider Opinion Studies 
 Three descriptive, web-based, studies were conducted with clinicians as 
participants. In these studies, investigators studied physicians, advanced practice nurses 
and physician assistants, and their opinions related to end-of-life care of patients with an 
LVAD and their experiences with LVAD deactivation.24-26 Clinicians who provided data 
for these studies included American cardiology clinicians,24 American hospice/palliative 
medicine clinicians,24,25 and European cardiologists.26 Investigators for these three studies 
used the same 41-item web based survey; however, investigators for only one study 
included qualitative free-responses related to questions chosen by the investigator.24 None 
of the investigators discussed validity or reliability of the survey instrument, or details 
related to development of the instrument. One investigator did describe domains in the 
survey, which included, “LVAD as a life-sustaining therapy”, “Complexities of the 
process of LVAD deactivation”, “Ethical and legal considerations of LVAD 
deactivation”, “Honoring requests for turning off an LVAD in a patient who is not 
nearing death”, and “Believe the underlying disease- heart failure- is the cause of death in 
a patient who dies after their LVAD is turned off”.24  
Overall, comparison among the various specialties and geographic locations 
revealed few similarities. Geographically, a greater proportion of Europeans physicians 
described death post-deactivation of the LVAD as “euthanasia or physician-assisted 




likely to report that they had deactivated an LVAD at the request of a patient compared 
with European physicians (European 50%, American 82%, p < 0.004).26 Investigators 
concluded that cultural, ethical, legal, historical, and socio-psychological variations can 
be based on geographical differences, and these differences are evident in clinicians 
opinions regarding end-of-life care with an LVAD.26 
 In the studies that examined hospice and palliative medicine providers and 
cardiology providers, significant differences between the two groups, and individually 
within the groups, can be seen.24,25 Hospice and palliative care medicine providers 
demonstrated a very high rate of involvement with deactivation or end-of-life discussions 
and experiences, with around 96% of clinicians involved with a deactivation of an 
LVAD.25 This involvement in care was much smaller in cardiology providers, with only 
42% being involved in the deactivation of an LVAD.26 Along with personal experiences 
of deactivation, a difference of opinion about the ethical permissibility of deactivation 
was also seen between the various clinician specialties. Hospice and palliative medicine 
providers believed that deactivation was a patient and caregiver decision, with 72% and 
88% in the various studies believing that a patient did not need to be “dying” to decide to 
deactivate their LVAD,24,25 while only 57% of cardiology providers believed that it would 
be acceptable to deactivate the LVAD if the patient is not actively dying.24 
 The qualitative portion of the web-based survey allowed participants to elaborate 
on their survey answers in an open-ended way.24 When answering the question of 
whether heart failure is the cause of death when an LVAD is deactivated, a cardiology 
clinician, specifically a cardiothoracic surgeon, stated that, “Turning off an LVAD from a 




care physician responded to the same questions by stating, “The act of turning off the 
machine is not the cause of death; the disease is the cause of death”, these dichotomous 
responses between the participants demonstrate the complex issues related to end-of-life 
decision making among providers of patients with an LVAD.24 
3.3.3 Quality Evaluation Results  
 In Tables 3.2, 3.3, and 3.4 quality evaluation of the various studies included in 
this review using the MMAT tool are presented. Overall, the majority of the articles had a 
low-quality rating, due to lack of information provided by authors related to 
methodology. The qualitative studies had slightly better overall quality compared to the 
quantitative studies, however, all three articles could have benefited from more 
descriptive quotes from the interviews to corroborate the conclusions made by the 
authors. The quantitative descriptive studies completed by Swetz et. al,25,26 needed much 
more explanation of the survey used, including reliability and validity statistics. These 
studies also lacked explanation for the low response rates, which could have led to biased 
conclusions. The mixed-methods study also lacked a description of exactly how the 
qualitative portion was integrated within the quantitative study, and how the results of the 
various methods agreed or disagreed with one another.21 
3.4 Discussion 
 Despite the high mortality rate of patients with an LVAD, there are still large gaps 
in our understanding of the various aspects of end-of-life care for patients, caregivers, 
and their clinicians. Investigators using qualitative methods determined that patients with 




end-of-life approached, and often had unanswered questions about what the end-of-life 
would be for them. This suggested that there was a lack of preparation and guidance of 
patients and their caregivers regarding end-of-life from health care providers. However, 
end-of-life care and decisions should be a point of emphasis for this population due to the 
nature of the underlying pathology, the high-risk of the LVAD surgery, and the potential 
for complications following implantation, including stroke and infection.7  
Despite the lower quality of the qualitative research, the conclusions reached by 
the investigators were all similar; providers of patients with an LVAD must do a better 
job educating their patients about end-of-life. Several investigators are currently involved 
in this kind of work; researchers are developing preparedness planning tools for LVAD 
patients and their families to ensure that before and after implantation, they know what to 
expect regarding deactivation and death, as well as incorporating teaching on advanced 
directives.16-18,27 These types of interventions could meet the needs voiced by many 
patients and caregivers in these studies, and create a more cohesive decision-making 
process at the end-of-life.  
 Results from the provider opinion studies may explain the frustration and 
confusion experienced by caregivers and patients with an LVAD. While addressing the 
needs of patients and caregivers through preparedness planning, we are missing a crucial 
stakeholder involved in the end-of-life decision making processes. Providers of patients 
with an LVAD also need more guidance about how to handle end-of-life decision making 
processes. To date, there have been no studies focused on provider education related to 
end-of-life with an LVAD, and this review demonstrates this is a major gap in this area. 




field,28 however, it does not seem that providers in other fields are changing their 
practices to ensure they are meeting the needs of this unique group of patients and their 
families. This provider gap could be attributed to the vague guidance provided by the 
professional organizations of their fields. There needs to be more guidance from 
professional organizations that advise providers about the ethical implications of 
deactivation, as well as in-depth guidance on the role of providers in educating patients 
and their families about end-of-life with an LVAD.  
 There is also a disconnect between patient and provider opinions on end-of-life 
discussions. Participants in the qualitative study expressed that they felt unprepared, and 
many say that had never had these types of end-of-life care discussions with their 
providers. However, providers in the quantitative studies often said they had experiences 
with these types of discussions with their patients and families. This could be due to a 
lack of conversation had between providers and their patients and families. Providers feel 
as though the subject has been broached by bringing up an area such as end-of-life, but 
patients and families may not have fully grasped what the providers were saying or did 
not feel that their needs were fully met. This could be an example of the lack of shared-
decision making. 
As discussed before, researchers in the field who have discussed end-of-life in 
published editorials acknowledge the lack of shared decision-making in these 
processes.12,13 This is seen in the confusion and frustration voiced by all shareholders in 
the area of end-of-life decision making for patients with an LVAD. More research 
emphasis needs to be placed on interventions that can increase and improve 




end-of-life discussions. This type of research could aim to identify gaps between what 
providers feel they are discussing with their patients versus what patients feel has been 
discussed, then interventions can focus on filling this gap. This type of shared decision-
making could also alleviate some of the ethical concerns that have arisen by having more 
open lines of communication between the various groups involved.  
While the literature review demonstrates several gaps regarding end-of-life care 
for patients with an LVAD, the ultimate gap is the lack of credible studies on the subject 
itself. Multiple types of studies, including quantitative, qualitative, and mixed-methods 
were included because there were not enough of any one type to create a comprehensive 
review. Moving forward, research must focus on creating high-quality studies that 
examine end-of-life with an LVAD for all the stake-holders, both through quantitative 
and qualitative methods, and examine the various system level factors associated with 
these decision-making processes.  
3.5 Limitations 
 There were several limitations of this review. Only articles published in English 
were included, so some studies with important conclusions may not have been evaluated. 
Second, due to the relative limited availability of studies, multiple different types of 
studies were included, which limited the ability of the reviewers to compare the studies to 
one another directly, therefore we used the MMAT tool to compare them. A primary 
limitation is the lack of investigations of end-of-life care, and the lack of high quality 
studies related to end-of-life care in patients with an LVAD, which leads to decreased 





 Based on the review of these six studies, providers, caregivers, and patients with 
an LVAD are struggling with end-of-life issues and care. There is a lack of provider 
education about end-of-life with an LVAD, and patients and their caregivers are 
experiencing high levels of confusion and frustration about what to expect at the end-of-
life. Further research is needed to create more comprehensive guidelines for end-of-life 
care for patients with an LVAD. Future studies should focus on patients with an LVAD 
experiences regarding end-of-life discussions with their provider and caregivers. 
Research is needed on providers’ experiences, attitudes, and knowledge about end-of-life 
discussions with their patients who have an LVAD, and quantitative analysis regarding 
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Potential to save or “being 
saved”- created a sense of 
moral obligation to 
undergo procedure 
“Living in liminal state”- 
patients describe 
uncertainty of what death 
with an LVAD would be 
like, lots of unanswerable 
questions to providers  
Brush 
(2010) 






Most patients did not 







patients with an 
LVAD as DT 
2 weeks of death 
of patient with an 
LVAD as DT) 
often when QOL was 
acceptable 
Open discussion with the 
LVAD team crucial 
All expressed relief when 
detailed plan for 
withdrawal was outlined   
Ongoing communication 
with LVAD team “in 
concert” with hospice 
teams very important to 







n= 8 bereaved 
caregivers of patients 





patients who died 
with an LVAD 
3 main themes: 1) 
overwhelmed with 
process of death with an 
LVAD, 2) different 
beliefs about the legal and 
ethical principles related 
to deactivation of the 
LVAD, and 3) lack of 




the EOL, was a major 
source of confusion and 
abandonment for 
caregivers.  
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deactivation of the 
LVAD and other 
LVAD EOL 
concerns  
Comparison of HPM and 
cardiology clinicians’ 
views on aspects of 
LVAD deactivation and 
EOL. Quantitative and 
qualitative evaluation 
demonstrated lack of 
consensus between 
providers. Authors 
concluded that this 
extreme difference in 
opinion could lead to 
confusions for patients, 
loved ones and other 













who care for patients 




clinician opinions on 
LVAD deactivation 
and EOL 
41 item web-based 
survey regarding 
deactivation of the 
LVAD and other 
LVAD EOL 
concerns  
There were several 
significant differences 
between European and 
North American 
clinicians. Europeans 
physicians were less likely 
to endorse the 
permissibility of 
deactivating the LVAD, 
as well as considering 
deactivation of the LVAD 
as physician-assisted 
suicide/euthanasia 
(p<.05). The researchers 
concluded that more 
consensus and guidance is 
needed to help clinicians 
regarding education of 
patients with an LVAD 











n= 122 hospice/ 
palliative care 
medicine clinicians 
41 item web-based 
survey regarding 
deactivation of the 




described the results 
related to HPM clinicians’ 
experiences and opinions 
regarding varying aspects 
of LVAD deactivation. 
The researchers concluded 
that compared to other 
physician groups HPM 
clinicians support the 
ethicality of LVAD 
deactivation and support 
patient autonomy.  
Legend: DT- destination therapy, EOL-end-of-life, HPM- hospice/palliative care 
medicine, LVAD- left ventricular assist device 
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Figure 3.1 Flow Chart of Articles Included in Integrative Review 
 
CHAPTER FOUR. PSYCHOMETRIC TESTING OF THE CONTROL-ATTITUDES 
SCALE-REVISE FOR PATIENTS WITH A LEFT VENTRICULAR ASSIST DEVICE 
4.1 Introduction 
Perceived control is a broadly studied construct that primarily focuses on an 
individual’s perception that they can positively influence outcomes related to stressful 
situations.1 In healthcare, perceived control is often linked with the ability to positively 
cope with a diagnosis and management of chronic disease, particularly heart failure 
(HF).2-4 As of 2018, HF affected approximately 6.5 million Americans.5 To treat end-
stage HF, many patients receive a left ventricular assist device (LVAD); since the 
development of these devices, over 17,000 people have received an LVAD and the 
















 Patients with an LVAD face much of the same disease burden as those with 
medically managed HF, however, patients with an LVAD have extremely unique needs 
related to life with a device.  Health related quality of life (HRQOL) is an evolving 
concept in the LVAD literature; researchers have shown that HRQOL is associated with 
anxiety and depression in patients with an LVAD, similar to other cardiac populations. 7 
It has been shown in the HF population that poor perceived control is related to decreased 
HRQOL, as well as strongly correlated with anxiety and depressive symptoms.2,8 In 
patients with an internal cardioverter defibrillator (ICD) a qualitative analysis revealed 
that perceived control was the core theme related to psychological adjustment to living 
with a device.9 Perceived control is often one of the main targets of nursing interventions, 
as it is considered modifiable factor. Despite understanding the critical role that perceived 
control plays in similar patient populations, perceived control has never been examined in 
the LVAD population.  
 To more thoroughly understand the role perceived control plays, it is critical to 
have a validated measure to assess it. Currently, the Control Attitudes Scale-Revised 
(CAS-R) is the primary perceived control assessment scale used in cardiac populations.8 
The purpose of this study was to evaluate the reliability and validity of the CAS-R in the 
LVAD population. The specific aims were to: 1) assess internal consistency and 
homogeneity of the CAS-R; and 2) provide evidence of construct validity with factor 
analysis and hypothesis testing using the following hypotheses: 
• Hypothesis 1a: Patients with higher levels of perceived control will have 




• Hypothesis 1b: Higher levels of perceived control will be independently 
associated with lower levels of depressive symptoms in a multivariate 
regression analysis  
• Hypothesis 2a: Patients with higher levels of perceived control will have 
lower levels of anxiety 
• Hypothesis 2b: Higher levels of perceived control will be independently 
associated with lower levels of anxiety symptoms in a multivariate 
regression analysis  
4.2 Background 
 The initial Control Attitudes Scale was created in 1995 by Moser and Dracup due 
to lack of a validated measure of perceived control in cardiac patients, and the relevance 
that perceived control had shown to possess in clinical practice.10 The initial four-item 
scale demonstrated good validity and reliability in several studies of cardiac patients,10,11 
however, the authors found that when a participant did not have a significant support 
person in their life, the scale had poor reliability.8 To address this phenomenon, the 
authors revised the initial four-item scale and added components from the Rheumatology 
Attitudes Scale;12 this revision and addition resulted in a 19-item Cardiac Attitudes 
Index.8  After extensive  psychometric evaluations of the 19-item scale, the authors 
deleted 11 items, leaving the 8-item CAS-R most commonly used in research today.8  
 The 8-item CAS-R was validated in a large cohort over 4,000 participants with 
various cardiac diseases and shown to have excellent reliability and validity.8 The 
Cronbach’s alpha of the sample was greater than 0.7, indicating good reliability.8 




relationship of perceived control to anxiety and depression. In prior studies, those with 
lower anxiety and depression symptoms had higher levels perceived control.10,11,13 
Validity was confirmed using hypothesis testing of these prior findings, showing in the 
sample of 4,000 cardiac participants that higher perceived control was associated of 
lower levels of anxiety and depressive symptoms.8  
 To our knowledge, perceived control has not been measured and reported in the 
LVAD population. As the LVAD population continues to increase in number, it is crucial 
to understand the role that perceived control plays in the QOL of these patients. In a 
systematic review of the literature related to quality of life with an LVAD, authors found 
that QOL is not well understood due to limitations of our current instruments to measure 
this concept.14 One finding that was consistent in this review was that adaptation to 
device management was a difficult process and that this process takes significant 
emotional and physical adaptation.14 Additionally in the LVAD population, levels of 
depression and anxiety are higher than in the general population, similar to that of other 
chronic disease states.15 However, we do not know the role perceived control may play or 
if it is valid measure of this concept in this population.  
4.3 Methods 
 In this secondary analysis of perceived control, depressive symptoms and anxiety 
symptoms in 89 patients with an LVAD. This sample was drawn from a larger 
prospective research study described in more detail elsewhere.16 Sociodemographic data 
were collected through self-report and inspection of the medical record. Institutional 





4.3.1.1 Control Attitudes Scale-Revised 
 The 8-item instrument (Table 4.2) was completed by each participant 
individually. The total score ranges from 8-40, with lower scores indicating lower levels 
of perceived control.8 Each scale item is rated on a 5-point Likert scale, with 1 being 
totally disagree, and 5 being totally agree. Item numbers 5 and 8 are reverse coded. The 
instrument is typically completed in less than 2 minutes and is between a fourth and fifth 
grade reading level.8  
4.3.1.2 Patient Health Questionnaire-9  
Depressive symptoms were measured using the Patient Health Questionnaire-9 
(PHQ-9), which consists of nine items. Each item corresponds to one of the nine 
symptoms of the major depressive disorder criteria of the Diagnostic and Statistical 
Manual of Mental Disorders-IV. Patients rated items based on how often they 
experienced these symptoms over two weeks on a 4-point Likert scale ranging from 0 
(not at all) to 3 (nearly every day). The scores are totaled with a range of 0 to 27. Higher 
scores on the PHQ-9 indicate higher levels of depressive symptoms. The reliability and 
validity of the PHQ-9 has been demonstrated extensively in a number of populations as a 
screening instrument for depression and a measure of depressive symptoms among those 
at risk for or with cardiac disease.17-19 The PHQ-9 had demonstrated high specificity and 
predictive value in relationship with other clinical measures of depression.17-19 In this 
sample of LVAD patients the Cronbach’s alpha was 0.845, indicating good internal 




4.3.1.3 Brief Symptom Inventory Anxiety Subscale 
 Anxiety symptoms were measured using the Brief Symptom Inventory (BSI) 
anxiety subscale. This is a 6-item subscale is used to measure the intensity of anxiety 
symptoms over the past 7 days.20 The items are scored on a 5-point Likert scale from 0 
(not at all distressed) to 4 (extremely distressed). The total sum of scores range from 0 to 
24, with higher scores indicating higher levels of anxiety symptoms. In this sample of 
LVAD patients the Cronbach’s alpha was 0.840, indicating good internal consistency.  
4.3.2 Data Analysis  
 All statistical analyses were conducted using SPSS version 24. Frequencies and 
percentages or mean and standard deviations were used to describe the sample. The 
sample was divided into high and low perceived control groups by the median score of 
the sample, due to the skewness of the data and recommendation of the initial author of 
the scale. Independent t-tests and chi-square tests were used to test for differences 
between the high versus low perceived control groups. A probability value of less than 
0.05 was considered to be statistically significant. 
4.3.2.1 Reliability 
 Internal consistency reliability was assessed using Cronbach’s alpha. A 
coefficient of greater than 0.7 is considered acceptable internal consistency reliability, a 
score of 0.8 is considered good internal consistency.21 Further reliability analyses were 
conducted using inter-item and item-total correlations to assess for homogeneity of the 
scale. Inter-item correlation coefficients greater than 0.2 and less than 0.7 demonstrate 




total correlations greater than 0.2 indicated that the scale items make an individual 
contribution to the scale.21 
4.3.2.2 Validity 
 Factor analysis was completed to test construct validity. We used exploratory 
factor analysis to examine the number of factors this scale measured in the LVAD 
population. Principal component analysis was utilized, and if more than one factor 
loaded, varimax rotation was used to provide a more complete understanding of the 
variance each item explained per factor. In order to ensure that factor analysis was 
appropriate, we evaluated the Kaiser-Meyer-Olkin statistic; higher values indicated that 
the sample would be appropriate for factor analysis.21 Bartlett’s test of sphericity was also 
examined to ensure that the correlation matrix of the items was not an identity matrix, 
which would indicate that factor analysis would not be appropriate.21 In Bartlett’s test, a 
p-value of less than 0.05 is indicative that the sample is appropriate for factor analysis.21 
In principal component analysis, Eigenvalues of one and above were retained. In the 
scree plot analysis, we will look for a point where the shape of the curve changes, this 
indicates that the factors above the curve change account for the most significant amount 
of variance.  
Convergent validity was verified using hypothesis testing. Two hypotheses were 
tested in which we examined the relationship of perceived control with depressive and 
anxiety symptoms. Prior research has shown that high levels of perceived control were 
related to lower levels of depressive symptoms and lower levels of anxiety 
symptoms;8,10,11 therefore, an instrument that is psychometrically established in the 




relationships between high levels of perceived control and lower levels of depressive and 
anxiety symptoms were tested.  
To test Hypothesis 1a, that higher levels of perceived control are associated with 
lower levels of depressive symptoms in LVAD patients, a two group, t-test analysis was 
utilized. High and low groupings of perceived control were used as the independent 
grouping variable, and total score on the PHQ-9 was used as the dependent variable. To 
test Hypothesis 1b, a multivariate linear regression analysis was used, with total score on 
the PHQ-9 as the dependent variable, and total score on the CAS-R, after controlling for 
age, gender, education level, and whether the participant lived alone.   
To test Hypothesis 2a, that higher levels of perceived control are associated with 
lower levels of anxiety symptoms in LVAD patients, a two group, t-test analysis was 
used. High and low groupings of perceived control were used as the independent 
grouping variable, and total score on the BSI anxiety subscale was used as the dependent 
variable. To test Hypothesis 2b, a multivariate linear regression analysis was used, with 
total score on the BSI anxiety subscale as the dependent variable, and total score on the 
CAS-R, after controlling for age, gender, education level, and whether the participant 
lived alone.  
4.4 Results 
 Baseline demographic information was collected prior to LVAD implantation, 
and other measures were collected 1-month post LVAD implant. Summary statistics for 
the sample are presented in Table 1. The CAS-R scores were slightly negatively skewed, 




used to divide the sample into two groups, high perceived control (46% of the sample) 
and low perceived control (54% of the sample). The sample was 80% male, which is 
consistent with the LVAD population in the United States currently.6 When comparing 
the high versus low perceived control groups, there were three significant differences 
between the groups (Table 4.1). Those with higher perceived control had significantly 
higher scores of the CAS-R, with a mean score of 34 ± 2.6, compared to those with lower 
perceived control whose mean scores were 25 ± 4.8. Those with higher perceived control 
also had on average lower scores on the PHQ-9 compared with those with lower 
perceived control. Lastly, those with higher perceived control had lower scores on the 
BSI Anxiety subscale compared to the lower perceived control group.  
4.4.1 Reliability 
 Cronbach’s alpha of the CAS-R was 0.867, indicating good internal consistency. 
Overall, the inter-item correlation coefficients were less than 0.8 indicating little to no 
redundancy among the items. All correlation coefficients were greater than 0.2, indicating 
that the items were related to one another (Table 4.3). Item-total correlations were all 
greater than 0.3, indicating that each item made a unique contribution to the scale (Table 
4.4). There were also no items from that scale that if removed would make the 
Cronbach’s alpha increase (Table 4.4), another indicator of good reliability of the scale.  
4.4.2 Validity 
 Construct validity was tested using exploratory factor analysis. To test that factor 
analysis was appropriate the Kaiser-Meyer-Olkin statistic was run, with a result of 0.828. 




appropriate to conduct in this sample. Through exploratory factor analysis, one factor 
loaded with an Eigenvalue of 4.183. This indicates that the CAS-R in the LVAD 
population is only measuring one construct. The factor explained 52% of the variance in 
the responses. Table 4.5 demonstrates the loadings of each individual items under the one 
factor.  
 In testing Hypothesis 1a, a two-group t-test demonstrated that the relationship of 
perceived control on depressive symptoms was significant (Table 4.6). When testing 
Hypothesis 1b, perceived control was independently associated with depressive 
symptoms in a multivariate linear regression analysis, including age, gender, education, 
and whether they lived with someone, as well as perceived control was the only 
significant predictor of depressive symptoms (Table 4.7).   
 In Hypothesis 2a, a two-group t-test demonstrated that the relationship of 
perceived control on anxiety symptoms was significant (Table 4.8). A multivariate linear 
regression analysis to test Hypothesis 2b included age, gender, education, whether they 
lived with someone, and perceived control and showed that perceived control was the 
only variable independently associated with anxiety symptoms in the model (Table 4.9).  
4.5 Discussion 
 The results of this study provide evidence that the 8-tem CAS-R is a reliable and 
valid measure of perceived control in the LVAD population. Reliability testing evidence 
from Cronbach’s alpha coefficient, inter-item correlations, and item-total correlations, 
indicate that the CAS-R had good internal consistency. Evidence of validity was also 




The CAS-R loaded on only one factor, indicating that the scale was only measuring one 
construct, that of perceived control. This is similar to other factor analyses done of the 
CAS-R.8 We were also able to observe that patients with LVAD who had higher levels of 
perceived control, had lower levels of anxiety and depressive symptoms, similar to other 
cardiac populations.8,13  
 It is critical to have a validated instrument of perceived control in this population 
because of our lack of understanding of predictors of good quality of life with an 
LVAD.14,15 In other populations, especially populations with a cardiac device, there is 
evidence of the important role that perceived control plays in positive outcomes,4,9,10,13 
however, this had not been demonstrated in the LVAD population. A reliable and valid 
scale will help clinicians and researchers to accurately identify the role perceived control 
plays in patients with an LVAD. Improving perceived control would ideally be a target 
for interventions that can improve quality of life and broaden our understanding of what 
life with a device truly entails.  
4.6 Conclusion 
 This study demonstrates that the CAS-R is a reliable and valid instrument to use 
in the LVAD population to measure perceived control. Clinicians and researchers can use 
the instrument to identify the role perceived control plays in outcomes of patients with an 








Table 4.1 Participant Characteristics, N= 89 
 All Participants,  
Mean±SD 










Age (years)  53 ± 14 53 ± 16 53 ± 12 0.844 
Gender (male)  81 (80.2) 55 (57) 41 (43) 0.538 
CAS-R  29.1 ± 6 34 ± 2.6 25 ± 4.8 <0.001 
PHQ-9  6.4 ± 5.3 4.3 ± 3.7  8.1 ± 6 <0.001 
BSI Anxiety Subscale  3 ± 3.6 1.9 ± 2.9 3.9 ± 3.9 0.005 
Legend CAS-R: Control Attitudes Scale-Revised; PHQ-9: Patient Health Questionnaire-9; 






Table 4.2. The Control Attitudes Scale-Revised 
Items 
1. If I do all the right things, I can successfully manage my heart condition 
2. I can do a lot of things myself to cope with my heart conditions 
3. When I mange my personal life well, my heart condition does not bother 
me as much 
4. I have considerable ability to control my symptoms 
5. No matter what I do, or how hard I try, I just can’t seem to get relief from 
my symptoms* 
6. I am coping effectively with my heart condition 
7. Regarding my heart problems, I feel lots of control 
8. Regarding my heart problems, I feel helpless* 






Table 4.3 Inter-Item Correlation of the CAS-R, overall Cronbach’s Alpha 0.867 
 Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 
Item 1 1.00        
Item 2 0.516 1.00       
Item 3 0.546 0.563 1.00      
Item 4 0.459 0.523 0.544 1.00     
Item 5 0.536 0.318 0.416 0.264 1.00    
Item 6 0.440 0.524 0.297 0.346 0.272 1.00   
Item 7 0.506 0.445 0.603 0.696 0.414 0.437 1.00  
Item 8 0.471 0.338 0.368 0.326 0.539 0.446 0.484 1.00 






Table 4.4. Item-Total Statistics for the CAS-R 
 Item-Total Correlation Cronbach’s Alpha if item 
deleted 
Item 1 0.687 0.844 
Item 2 0.629 0.850 
Item 3 0.667 0.846 
Item 4 0.626 0.851 
Item 5 0.532 0.860 
Item 6 0.531 0.860 
Item 7 0.725 0.838 
Item 8 0.574 0.856 






Table 4.5 Factor Loadings for the CAS-R  
 Loadings for Factor 1 
Item 1 0.779 
Item 2 0.735 
Item 3 0.762 
Item 4 0.731 
Item 5 0.639 
Item 6 0.639 
Item 7 0.804 
Item 8 0.676 
 
Table 4.6 Differences in depressive symptoms based on high versus low levels of perceived 
control  (N=89) 





PHQ-9 Total Score 8 ± 6 4.4 ± 3.7 0.001 
Legend: F statistic 11.915, Brown-Forsyth p-value 0.001 (Levene p-value 0.002); PHQ-9- 





Table 4.7 Multivariate Linear Regression Model: Perceived control as an independent predictor 
of depressive symptoms (N=89) 
 Beta 95% Confidence 
Interval 
b SE P-value 
CAS-R total 
score 
-0.392 -0.563- -0.222 -0.446 0.086 <0.001 
Age 0.013 -0.063-0.088 0.033 0.038 0.740 
Gender (male) 1.295 -1.163-3.753 0.102 1.236 0.298 
Education 
Level 






-0.372 -3.658- 2.915 -0.022 1.652 0.823 
Legend: overall p-value 0.001; B: standardized beta coefficient; SE: standard error; overall 






Table 4.8 Differences in anxiety symptoms based on high versus low levels of perceived 
control (N=89) 





BSI Anxiety Subscale 
Total Score 
3.9 ± 3.9 1.9 ± 2.9 0.005 
Legend: F statistic 8.127, Brown-Forsyth p-value 0.005 (Levene p-value 0.035); BSI- Brief 






Table 4.9 Multivariate Linear Regression Model: Perceived control as an independent predictor 
of anxiety symptoms (N=89) 
 Beta  95% Confidence 
Interval 
b SE P-value 
CAS-R total 
score 
-0.186 -0.308--0.065 -0.317 0.061 0.003 
Age 0.002 -0.052-0.056 0.007 0.027 0.947 
Gender (male) 1.338 -0.410- 3.086 0.157 1.236 0.132 
Education 
Level 






-0.317 -2.653- 2.020 -0.028 1.652 0.788 
Legend: overall p-value 0.047; B: standardized beta coefficient; SE: standard error; overall 
adjusted r-square 0.071 
 
CHAPTER FIVE. END-OF-LIFE ATTITUDES AND EXPERIENCES OF PATIENTS 





Patients with advanced heart failure (HF) were historically treated with medical 
management only; however, in the last 10 years the use of advanced surgical treatment 
options, such as a left ventricular assist device (LVAD), have become viable treatment 
options. Since the Food and Drug Administration (FDA) first approved LVADs for use as 
bridge to heart transplantation in 1994, the science and rapid utilization of these devices 
has grown exponentially.1 Between 2008 and 2017, over 17,000 LVAD’s were implanted 
in the United States,2 and that number will continue to grow due to the lack of available 
donor hearts and the growing number of Americans with HF.3,4 
 While scientific advancements such as LVADs increase life expectancy in some 
individuals compared to optimal medical management,5 most recent data show that the 
there is still a high mortality rate at one year of about 19%,2 and at times, poorer quality 
of life than without an LVAD.6 The most common causes of death in the LVAD 
population are neurologic complications, multi-system organ failure, and infection.7 
There is also a possibility of pump thrombosis, which occurs when a large clot obstructs 
flow through the device, causing the device to malfunction. When this occurs, a pump 
exchange usually is required; however, patients who have a pump exchange exhibit much 
higher rates of mortality compared to patients who have only one pump in their lifetime.7 
Pump exchanges related to thrombus occur in about 7% of patients in the first year, and 
up to 18% at year two.8 Thus, despite the life-prolonging capacity of LVADs, there are 
still significant risks associated with the device that can ultimately lead to death.  
Because of the high mortality rates, and increased morbidity and mortality 
associated with pump exchanges,8 it is critical that patients who have been implanted 




care. However, many LVAD providers have limited experience with deactivation, with 
only 42% of American cardiologists having been involved in the care of a patient who 
had their device deactivated.9 There are differing opinions among providers on how to 
approach EOL discussions with patients who have an LVAD, and whether deactivation is 
an ethical option.9-11 As a result of lack of provider consistency and knowledge on 
broaching EOL discussions with this population, patients and caregivers often express 
confusion and uncertainty about options for EOL with an LVAD, and report frustration 
when attempting to get information from providers.11,12  
 The high incidence of cognitive impairment in patients with HF compounds 
difficulties in shared decision making among patients, caregivers and providers.13 
Cognitive impairment leads to blunted responses of HF patients, difficulty responding in 
conversations, or slower responses to physiologic symptoms that indicate the need for 
intervention.14 Mild cognitive impairment in the HF population is associated with higher 
rates of readmissions and death,15 thus necessitating more urgent and thorough EOL 
conversations.  
To provide support and education for patients with an LVAD, an exploration of 
experiences and attitudes about EOL issues is needed. Specifically, there is a need to 
focus on patients’ feelings about living with their LVAD within the context of another 
terminal illness or worsening of current illnesses, while also considering the impact of 
cognitive function. This will help clinicians understand how experiences and attitudes 
about the LVAD influence patient preferences when nearing EOL. The purpose of this 




deactivation and pump exchange and examine the impact of cognitive status on these 
attitudes and experiences. The specific aims of this study were to:  
Specific Aim 1: Describe patients’ attitudes and experiences of discussions with their 
healthcare about pump exchange and LVAD deactivation at EOL.  
Specific Aim 2:  Determine the association of cognitive function with patients’ attitudes 
and experiences toward pump exchange and LVAD deactivation.  
5.2 Methods 
5.2.1 Sample, Study Design, and Data Collection 
 This study was a cross-sectional correlational design. Patients with an LVAD 
invited to participate met the following inclusion criteria: 1) had an implanted LVAD for 
the treatment of end-stage heart failure; 2) LVAD was implanted for at least 30 days prior 
to enrollment in the study; 3) able to complete a three-question cognition assessment and; 
4) able to speak and write English. Exclusion criteria were: 1) less than 18 years of age 
and 2) institutionalized or resided in an extended care nursing facility. Participants were 
screened by a recruiter for eligibility. Those who met inclusion criteria and agreed to 
participant were referred to the project directors who met with the participants to obtain 
informed consent. Participants were asked to complete a questionnaire packet and 
received $20 compensation for their time. Data collection took place between November 
2018 and February 2019. This study was approved by the Institutional Review Board at 
the University of Kentucky.  




 Demographic data and health history were self-reported. Lab values, information 
about LVAD therapy, such as pump exchange history, and implantable cardioverter 
defibrillator (ICD) implantation were obtained through review of patients’ medical 
record. Information regarding implant indication (destination therapy versus bridge to 
transplant), date of implantation, pre-operative New York Hospital Association (NYHA) 
class, and Intermacs profile (a clinical profile of health status at time of LVAD 
implantation) were collected using the Intermacs database.  
5.2.3 End-of-life with an LVAD Questionnaire  
 Patients’ experiences and attitudes about EOL were collected using a survey 
initially created for patients with an implantable cardioverter defibrillator that was 
modified to reflect the LVAD patient perspective.16 The End-of-Life with an ICD 
Questionnaire (EOLICDQ) was modified with the assistance of the developer and the 
modified instrument was called the End-of-Life with an LVAD Questionnaire (EOL-
LVADQ). The EOL-LVADQ is a 22-question survey that focuses on patients’ attitudes 
and experiences about decision making surrounding EOL, specifically deactivation of the 
LVAD and pump exchanges. Participants responded to the statements with either 
agree/disagree, yes/no, or cannot take a stand. The items on this survey are not scored, 
and therefore are not totaled; the items should be evaluated individually and responses 
can be compared. The last six questions on the survey allowed participants to respond 
with agree/disagree or ‘can’t take a stand’. Because, very few participants chose the 
‘can’t take a stand’ response, those who chose this response were not included in the 
analysis.  




 Cognition was evaluated in this study using the Montreal Cognitive Assessment 
(MoCA), which is a brief cognitive screening tool, widely used in multiple populations to 
identify mild cognitive impairment (MCI).17 Mild cognitive impairment is commonly 
understood as a decline in one or more cognitive functions, which is not attributed to 
other neuro-cognitive diseases such as dementia or Alzheimer’s.17,18 The MoCA has been 
validated in the heart failure population as a reliable measurement of cognition and 
MCI.19 The range of scores on the MoCA is 0-30. The cut-point recommended by the 
authors was used in this study. Thus, a score of 0-25 was considered to meet the criteria 
for MCI and scores 26 and above were categorized as normal cognition.18,20 
5.2.5 Data Analysis  
  SPSS version 24 was used for data analysis. Frequencies and proportions, means 
± standard deviations, and median, 25th, and 75th percentiles were used to describe 
demographic and clinical characteristics. Comparison of demographic and clinical 
characteristics, as well as experiences and attitudes about EOL decision making between 
normal cognition and MCI groups was completed using X2 and independent t-tests. 
Logistic regression analysis was used to determine whether MoCA score was an 
independent predictor of whether participants had discussed end-of-life scenarios or 
pump exchange with their providers. A p-value of less than 0.05 was considered 
statistically significant.  
5.3 Results  




 A total of 30 participants completed the questionnaire (Table 5.1), but one was 
unable to complete the MoCA and was excluded from subsequent analyses. The majority 
of the sample was male (76.7%), white (90%), and married (50%).  Most were NYHA 
class IV (70%) prior to implant, and had an Intermacs profile score of 2 or 3 (76.7%), 
indicating progressive or acute decline of health status requiring inotropic support. Most 
participants at the time of their interview had an LVAD implanted for destination therapy 
(63.3%), indicating they were not currently a candidate for heart transplantation. The 
mean number of days with LVAD therapy was 702, with a range of 34 days to 2,472 
days. Most participants had an implantable cardioverter defibrillator (83.3%), and had not 
had a pump exchange (90%). There was a high incidence of comorbidity burden in the 
population. A total of 46.7% of the total sample had diabetes, 53.3% reported 
hypertension, 20% had kidney failure, 60% reported either a history or current atrial 
fibrillation, and 33.3% reported some type of lung disease, either chronic obstructive 
pulmonary disorder or asthma. Four (13.3%) participants also reported a history of a 
stroke in the past, and 12 (40%) reported they had a myocardial infarction prior to LVAD 
implantation.  
5.3.2 Cognitive Assessment  
In the final sample of 29 participants, the average MoCA score was 23 ± 4, with 
23 of the 29 participants (79%), scoring less than a 26 indicating MCI. The average score 
of those participants with MCI was 22 ± 3, and the average score of those with normal 
cognition was 28 ± 1 (p<0.001).  Demographically, both groups were very similar, 




likely to be bridge to transplant patients (83.3%), compared to those with MCI (26.1%, p-
value 0.010; Table 5.1).  
5.3.3 End-of-Life with an LVAD Questionnaire 
To describe patients’ experiences and attitudes related to EOL decision-making, 
responses from the EOL-LVADQ were evaluated. Overall, 69% of the participants 
responded that they had discussed a pump exchange with their provider, and 58.6% said 
they had discussed what turning off the LVAD involves with their provider. Only 3.4% 
of the participants had ever considered asking their provider to turn off the LVAD at 
some point. Over 80% of participants said they would want to have a pump exchange 
even if their quality of life had not improved with their first pump, and 73% said they 
would want to have a pump exchange even if they were seriously ill and suffering from 
another disease besides HF. Only 48.3% of participants said they had discussed their 
wishes regarding EOL and their LVAD with the next-of-kin, despite 75.9% stating they 
had discussed their illness trajectory with their next-of-kin. When discussing when 
providers should bring up questions regarding deactivation, 44.8% of the participants said 
they would prefer to never have a deactivation discussion. A total of 86.2% thought that 
toward the EOL, during the final days, deactivation should be discussed, but only 51.7% 
said they felt it should be discussed if they were suffering from a different disease with a 
poor prognosis, such as cancer.  
To determine if cognition was associated with EOL decision making, we 
compared the responses of participants who had a MoCA score of 0-25 (MCI) and those 
with MoCA scores 26 and greater (Table 5.2). In general, there was very little variation in 




the two cohorts was that those who had MCI were more likely to report that they would 
like to decide themselves if their LVAD was deactivated towards the EOL (p = 0.017). 
Otherwise, the cohorts responded similarly.  
5.3.3.1 Logistic Regression Analysis  
Although a sample of 30 LVAD patients is considered relatively large in the 
LVAD arena (only about 2500 LVADs are implanted each year), statistically it is small 
and, we were unable to generate a stable regression model to evaluate the relationship 
between cognition and EOL decision-making, controlling for other relevant covariates. In 
bivariate analysis, total MoCA score was not a predictor of having a conversation with 
provider or next-of-kin regarding discussions related to deactivating the LVAD or pump 
exchange.  
5.4 Discussion 
 The analysis we conducted provides initial insight for researchers and clinicians 
to have a more thorough understanding of what patients with an LVAD have experienced 
and feel about EOL decision making. Due to the high rates of mortality and life-
threatening complications associated with LVAD implantation, EOL conversations and 
decision making are imperative. In order to be prepared for adverse events that may 
occur, guidelines provided by professional organizations urge LVAD teams to discuss 
EOL care, and integrate palliative care with patients and their families, even prior to any 
EOL scenario.21,22 Over 40% of our sample did not discuss deactivation of the LVAD 
device and or pump exchange with their providers and their next-of-kin even though the 




participants had discussed their wishes about EOL care with their next-of-kin, who would 
be their primary decision maker if they became incapacitated toward the EOL.  
 The recent Intermacs analysis showed over 75% of LVAD patients die in the 
hospital.23 This finding is important because in a large systematic review, researchers 
found that dying at home is the primary preference of most patients and an indicator of 
better EOL care.24 Shared decision making regarding preferences and plan for EOL care 
among patients, next-of-kin, and providers, may increase the possibility for patient 
preferences to be honored at the EOL and decrease frustration and confusion that often 
occurs for patients with an LVAD and their caregivers.25 
 We saw no differences between our participants with normal cognition and those 
with MCI. In the future, we may need to consider whether a higher threshold for MCI 
affects EOL decision making in a larger sample. Further analysis may want to focus on 
whether there are specific areas of cognition that are related to EOL decision making, 
such as language, abstraction, or memory, which may individually be more impactful 
than cognition as a whole. It would also be important to analyze whether depression or 
anxiety are associated with these relationships, as people with MCI have higher rates of 
depression and anxiety than those without MCI, which may have confounded our 
results.15 
 It is also important to recognize that many of our patients did not want to have an 
EOL conversation. As providers and researchers, it is imperative to find ways to integrate 
these crucial conversations into standard care, and promote the benefit of decreased 
confusion and make the EOL process less stressful. Many national organizations across 




as The Conversation Project and Caring Connections which aim to inform the general 
public about the importance of discussing the EOL with loved ones.26  Through open 
conversations between stake-holders in EOL decision-making, painful and confusing 
scenarios could be avoided, such as being shocked inappropriately by an implantable 
cardioverter defibrillator, or being unaware of the ability to deactivate the LVAD device 
in the setting of a terminal illness. The additional layers added to EOL care created by 
having a cardiac device necessitate the need and importance of communicating about 
EOL scenarios prior to an EOL situation.  
 In addition to EOL discussions, it is crucial the providers continue to educate 
patients and their families regarding the purpose of the LVAD and the limitation of pump 
exchanges. In this study, over 25% of the population said they would want a pump 
exchange even if they were suffering from another terminal illness such as cancer, and 
81% said they would want a pump exchange despite their quality of life not improving 
with the first pump. Providers need to ensure patients are aware of the risks that pump 
exchange can create, and if scenarios arise what situations might prompt a discussion 
related to end-of-life versus a pump exchange surgery. It seems there are many 
misconceptions related to when a pump exchange would be an acceptable treatment 
option, especially in the setting of another terminal disease besides HF, and with more 
guidance and education from providers, these misconceptions could decrease. However, 
these notions of persevering, despite life-threatening obstacles, are supported by findings 
that although most people say they want higher quality of life, compared to quantity of 
life,27 when EOL situations occur, many individuals change their minds and choose life at 




 Misunderstandings about LVADs and lack of EOL discussions with providers 
may also be related to lack of provider knowledge about EOL decision making. Providers 
of patients with LVADs also struggle to know what their role is and how to educate 
patients and family members about the decision making processes.28 In an analysis of 
cardiologists and palliative care physicians who routinely take care of patients with an 
LVAD, researchers found that there are several different perspectives among providers, 
and that this may lead to increased confusion for patients and their caregivers due to 
varying opinions or lack of opinions voiced by the physicians who take care of them.28 In 
the future, more emphasis is needed on the role that providers play in informing patients 
and families regarding EOL scenarios, and ensure that they have adequate understanding 
of how the device functions in various EOL scenarios.  
 In a recent qualitative study, patients with an LVAD and their caregivers had a 
mind set about ‘being saved’ and feeling a moral obligation to continue fighting no 
matter the obstacles.29 This sense of moral obligation to continue fighting, and a sense 
that this expensive and complex device saved their lives, so patients’ feel a need to 
continue fighting and persevering, despite threats of mortality, may be related to patients 
not wanting to discuss EOL with their providers, as well as a mentality to continue with 
treatments despite life-threatening diagnoses.  
Moving forward, more emphasis is needed to ensure patients and their families 
have a realistic expectation of life with an LVAD and that EOL discussions are had prior 
to implantation and continued throughout care. We also need to ensure that providers are 
equipped with the skills and knowledge to discuss EOL decision making throughout the 




decision making, we could prevent confusing, painful, and frustrating situations that may 
arise at the EOL for family members and patients with an LVAD.  
5.5 Limitations 
 The sample was from a single-center, thus limiting generalizability. The end-of-
life questionnaire was based on hypothetical scenarios which can be problematic for 
applicability and generalizability, however, to get data about this type of information, 
self-report is the only way. The sample size was small, and may not have been powered 
strong enough to conclude there was no differences between groups, however, in the 
LVAD literature, 30 LVAD patients is quite large and thus may be an adequate sample 
size.  
5.6 Conclusions 
 End-of-life decision making for patients with chronic illness is a complex process, 
and adding advanced medical technology to that process can increase complexity. 
Approximately half of our population had discussed EOL decisions with their providers 
or their next of kin, indicating a large gap in care. Patients who had MCI, which was 
around 80% of our sample, did not have different experience and attitudes regarding EOL 
decision making. More emphasis needs to be placed on educating patients and their 
families about these difficult decisions made at the EOL, as well as educating providers 
about ways to discuss EOL scenarios with patients. By improving these conversations 
and understanding what may influence EOL decision making, we can hopefully improve 
decision making processes for patients with an LVAD and their families when they reach 




Table 5.1 Participant characteristics for the total sample and compared between those with and 
without mild cognitive impairment 









Age (years) 57 ± 16, 
range 21-79 
60 ± 14 45 ± 19 0.135 
Sex: male, n (%) 23 (76.7) 17 (73.9) 5 (83.3) 0.620 
Race n (%)     
     White 27 (90) 20 (87) 6 (100) 0.224 
     Black or other minority 3 (10) 3 (13) 0 (0) 0.224 
Marital status n (%)     
     Single 7 (23.3) 4 (17.5) 3 (50) 0.141 
     Married 15 (50) 11 (47.8) 3 (50) 
     Divorced/Separated/Widowed 8 (267) 8 (34.8) 0 (0) 
NYHA classification, n (%)     




     IV 21 (70) 17 (77.3) 4 (66.7) 
Intermacs Profile, n (%)     
     1 4 (13.3) 3 (13.6) 1 (16.7) 0.754 
     2 6 (20) 5 (22.7) 1 (16.7) 
     3 17 (56.7) 12 (54.5) 4 (66.7) 
     4 2 (6.7) 2 (9.7) 0 (0) 
Indication, n (%)     
     Destination Therapy 19 (63.3) 17 (73.9) 1 (16.7) 0.010 
     Bridge to Transplant 11 (36.7) 6 (26.1) 5 (83.3) 
ICD Therapy, n (%) 25 (83.3) 19 (86.4) 5 (83.3) 0.853 
Days with LVAD Therapy 702 ± 589, 
range 34 - 
2472 
702 ± 408 408 ± 478 0.218 
Pump Exchange, n (%) 3 (10) 2 (9.1) 1 (16.7) 0.612 
Diabetes, n (%) 14 (46.7) 11 (47.8) 2 (33.3) 0.525 
High Blood Pressure, n (%) 16 (53.3) 12 (52.2) 4 (66.7) 0.525 
Kidney Failure, n (%) 6 (20) 5 (22.7) 0 (0) 0.198 




Stroke, n (%) (n=28) 4 (13.3) 4 (18.2) 0 (0) 0.302 
Atrial Fibrillation, n (%) (n=26) 18 (60) 13 (68.4) 4 (66.7) 0.936 
History of Myocardial Infarction, n 
(%) (n=27) 
12 (40) 8 (42.9) 2 (40) 0.907 
MoCA total score 23 ± 4, range 
14 - 29 
22 ± 3 28 ± 1 <0.001 
BUN, median [25th,75th]     
     Pre-implantation (n=28) 19 [17,30.25] 22 [18,34] 16 
[11.25,21.25] 
0.030* 







Creatinine, median [25th,75th]     














NT-ProBNP, median [25th,75th]     

















BMI, median [25th,75th]     














Legend: Data are shown as mean±SD, except as noted. BUN- Blood urea nitrogen, ICD- 
Implantable cardioverter defibrillator, LVAD- left ventricular assist device, MoCA- Montreal 
cognitive assessment, NT-ProBNP- NT-proB-type Natriuretic peptide, NYHA- New York 
Hospital Association Class. All comparisons for normally distributed were conducted using C2 
likelihood ratios for nominal and ordinal level variables, independent sample paired t-test for 
continuous level variables, and ANOVA for more than two group comparison variables, for 
non-normally distributed continuous data a Mann-Whitney U test was conducted as denoted by 






Table 5.2 End-of-Life Questionnaire responses compared between those with and 





















19 (65.5) 15 (65.2) 4 (66.7) 0.947 
Q. 3 Discussed 













16 (55.2) 13 (56.5) 3 (50) 0.775 
Q.5 I have 
discussed illness 
trajectory of my 
heart disease 
with my 
provider: yes   
23 (79.3) 17 (73.9) 6 (100) 0.075 
Q.6 I have 
discussed illness 




22 (75.9) 16 (69.6) 6 (100) 0.052 








LVAD at the 
end-of-life 




provider to turn 
off my LVAD 
1 (3.4) 1 (4.2) 0 (0) 0.492 
Q.9 I have a 
religious faith or 
outlook which 
helps me manage 
my daily life as 
an LVAD patient  
19 (65.5) 15 (65.2) 4 (66.7) 0.947 





9 (31) 8 (34.8) 1 (16.7) 0.372 




Each question began with the phrase: When should providers raise question of what 
turning off the LVAD involves?  
Q. 11 I never 




13 (44.8) 9 (39.1) 4 (66.7) 0.226 
Q.12 I myself 
will raise the 
question when I 
feel the need to: 
agree 
22 (75.9) 19 (82.6) 3 (50) 0.115 
Q. 13 If I am 
suffering from a 
disease with a 
poor prognosis 
other than HF: 
agree 
15 (51.7) 12 (52.2) 3 (50) 0.924 
Q. 14 Routinely 
upon visits to 






Q. 15 Towards 
the end-of-life, 
during the last 
days: agree 
25 (86.2) 21 (91.3) 4 (66.7) 0.153 
Q.16 If my 
LVAD has a 
mechanical 
malfunction or 
has a clot in it: 
agree 
18 (62.1) 14 (60.9) 4 (66.7) 0.793 
Attitudes domain cont. n (%) 
Each of the following questions began with the phrase: I want to have a pump 
exchange… 
Q.17* Even if 
my quality of 
life has not 
benefitted: yes 
21 (80.8) 17 (85) 4 (66.7) 0.340 
Q.18* Even I 
am seriously ill 






disease: yes  
Q. 19* Even if I 
have reached an 
advanced age: 
yes 
15 (57.7) 10 (50) 5 (83.3) 0.130 
Attitudes domain cont. n (%) 
Each of the following questions began with the phrase: When I find myself at the end-
of-life… 
Q.20** I wish 
to decide myself 
if the LVAD is 
turned off or 
not: yes 
22 (81.5) 20 (90.9) 2 (40) 0.017 
Q.21^ I want 
the doctor to 
decide if the 
LVAD is turned 
off or not 






to decide if the 
LVAD is turned 
off or not 
18 (66.7)   3 (50) 0.336 
Legend: LVAD- left ventricular assist device; MoCA- Montreal Cognitive 
Assessment; Samples that were not n=29 denoted by the following: *n=26, **n=27, 
^n=24- this is related to patients who chose ‘I cannot take a stand’ and were considered 
missing data. All comparisons were conducted using C2 likelihood ratios. A p-value of 






CHAPTER SIX. Conclusion 
6.1 Background and Purpose 
 The overall purpose of this dissertation was to examine patients’ attitudes and 
experiences related to end-of-life conversations involving their left ventricular assist 
device (LVAD) or implantable cardioverter defibrillator (ICD), and factors associated 
with end-of-life decision making. The following manuscripts were included in this 
dissertation: 1) a secondary data analysis of a national cohort of patients with an ICD in 
Sweden to identify factors associated with having a conversation about end-of-life with 
their providers, 2) an integrative review of the literature focused on end-of-life with an 
LVAD from the various stakeholders involved in end-of-life processes, 3) an evaluation 
of the psychometric properties of the Control Attitudes Scale-Revised (CAS-R) in 
secondary data analysis of patients with an LVAD, and lastly 4) a cross-sectional 
correlational study examining experiences and attitudes related to end-of-life and the 
relationship of cognition in patients with an LVAD.  
 With heart disease being the leading cause of death in the United States, end-of-
life decision making is crucial for those affected by cardiac disease.1 To treat the high 
rates of mortality, cardiac devices have become common, with close to 1.8 million 
Americans having either an LVAD or ICD.2,3 However, despite the increased use of these 
devices, healthcare providers have done a poor job of informing patients about the 
involvement of these devices at the end-of-life. Results from numerous studies 
demonstrate patients with an ICD experience inappropriate shocks towards the end-of-
life, even in the minutes before death, leading to unnecessary pain and suffering.4-6 




end-of-life due to a lack of planning and discussion related to end-of-life care, and in 
particular how to integrate the LVAD into end-of-life plans.7,8  
 The purpose of this chapter is to summarize and synthesize the findings of the 
manuscripts presented in this dissertation. It will examine how the outcomes of these 
findings will impact and further the state of the science regarding end-of-life decision 
making in patients with a cardiac device. Lastly, it will recommend changes regarding 
practice and recommendations for research related to end-of-life care and decision 
making in cardiac populations.  
6.2 Summary of Findings 
 Chapter Two is a secondary data analysis of a national cohort study of Swedish 
patients with an ICD, with and without heart failure, comparing end-of-life attitudes, 
experiences, knowledge, and factors associated with having a discussion about ICD 
deactivation with a healthcare provider. This study included 3,067 people with an ICD, 
and 1,461 (47%) stated they had heart failure. Despite our hypothesis that participants 
with HF would have a more comprehensive understanding of end-of-life due to their 
higher risk of mortality, we found no differences between the cohorts in their responses 
to the end-of-life with an ICD questionnaire.  Subsequently, we conducted a hierarchal 
logistic regression analysis to identify independent predictors of having a discussion with 
their healthcare provider regarding end-of-life scenarios. In the final model, the 
significant predictors were having high level of ICD concerns, having had an ICD shock 
in the past, and having a high level of anxiety (p<0.001). In this analysis, we found that 
our cohort had consistent results with other studies which have demonstrated patients are 




participants stating they never wished to have an end-of-life discussion with their 
providers. These findings suggest more research is needed to assess willingness to 
participate in end-of-life discussions and evaluate the best ways to incorporate shared-
decision making into end-of-life decision making in patients with an ICD.  
 Chapter Three is an integrative systematic review of the literature on the current 
evidence related to the process and content of end-of-life discussions with an LVAD and 
end of life discussion experiences of individuals, families, and healthcare providers of 
patients with an LVAD. Overall, there was very little evidence regarding decision making 
and end-of-life processes with an LVAD; only six articles were included in this review. 
Patients with an LVAD and their caregivers expressed frustration and confusion related 
to end-of-life processes associated with dying with an LVAD, and many stated they felt 
completely unprepared for the decisions they would have to make towards the end-of-
life. The opinions of healthcare providers of patients with an LVAD suggested that there 
is controversy related to the ethical permissibility of deactivation of the LVAD, as well as 
a divide regarding practices at the end-of-life for patients with an LVAD. The evidence 
suggests more research is needed to understand the current healthcare practices related to 
end-of-life care for patients with an LVAD, as well as increased education for providers 
about end-of-life processes and the ethics surrounding deactivation of the LVAD in order 
to develop a consensus about these topics.  
 Chapter Four is an evaluation of the validity and reliability of the CAS-R in a 
cohort of patients with an LVAD. This was a secondary analysis of a longitudinal study 
of 89 patients with an LVAD. Cronbach’s alpha in this examination was 0.867 indicating 




were all greater than 0.4 and less than 0.8, indicating homogeneity of responses and lack 
of redundancy among the items in the instrument. To examine convergent validity, 
hypothesis testing was used. We confirmed associations between lower depressive 
symptoms and lower anxiety symptoms, and higher levels of perceived control, 
correlating with other studies that have demonstrated prior relationships among these 
concepts.12 Overall, the results of this psychometric evaluation support the use of the 
CAS-R in the LVAD population, and can be utilized to in future studies as a target for 
interventions which aim to improve decision making processes for patients.  
 Chapter Five is a primary data analysis of a cross-sectional, correlational study of 
30 patients with an LVAD, examining end-of-life attitudes and experiences and the 
impact of cognition on these processes. Of the 29 participants able to complete cognitive 
testing, 23 (79%) had scores indicative of mild cognitive impairment (MCI). There were 
no differences in the attitudes or experiences related to end-of-life between the 
participants who had MCI and those with normal cognition. Overall, 41% of the cohort 
had never discussed end-of-life with their provider, and 30% had never discussed what an 
LVAD pump exchange would involve. Forty four percent of the participants said they 
never wanted to have a discussion with their provider regarding end-of-life situations 
involving their LVAD. There were also several alarming attitudes regarding LVAD pump 
exchanges, with 73% saying they would want to have a pump exchange even if they were 
seriously ill and suffering from a terminal disease other than heart failure. Despite 
patients with MCI having higher mortality rates in the heart failure population,13 those 
with cognitive impairment in this study had similar end-of-life attitudes and experiences. 




end-of-life and pump exchanges in the LVAD population and future research should 
continue to focus on identifying factors associated with these processes.   
6.3 Impact of Dissertation on the State of the Science 
 Despite the increasing prevalence of cardiac devices to treat cardiac disease, 
especially end-stage heart failure,3 there is still a gap in that providers are not fully 
preparing patients for end-of-life scenarios they may face with a device in place. In 
patients with an ICD, it is common for patients to be shocked inappropriately toward the 
end-of-life.6 Further, despite recommendations from providers about device deactivation 
and the role of the ICD at the end-of-life, many patients are still reluctant to deactivate 
their device,10,11 and do not include information about the device in their advanced 
directives.9,14 In patients with an LVAD and their caregivers, frustration and confusion is 
the overarching theme related to end-of-life care and discussions.7,8 This is further 
compounded by the fact that among providers of patients with an LVAD, there is a lack 
of consensus on how to handle end-of-life scenarios and questions of ethical 
permissibility of deactivation of the device.15,16 In both cohorts of patients, there is a lack 
of guidance from professional organizations about topics that need to be addressed end-
of-life scenarios, and scenarios in which it is acceptable to deactivate a device.17-19 
 Through this dissertation, I have advanced the state of the science of end-of-life 
decision making in patients with a cardiac device by: 1) identifying factors related to 
having a discussion with your provider in regards to deactivation of an ICD, 2) 
identifying overarching themes related to end-of-life opinions and experiences of the 
shareholders involved in end-of-life decision-making processes, 3) identified an 




target in future interventions related to end-of-life decision making, 4) and described 
experiences and attitudes related to end-of-life discussions related to deactivation and 
pump exchange in a cohort of patients with an LVAD.  
 In a large cohort of ICD patients I identified factors that were significantly 
associated with having a discussion with their provider regarding end-of-life. 
Understanding that end of life discussions are predicted by having an ICD shock, having 
a high level of concerns related to the ICD, and high levels of anxiety can help identify 
individuals in larger populations who may be more willing to have end-of-life 
discussions.  I also established that there are large segments of the population who never 
want to have end-of-life discussions, and isolated a new group of people who may need 
more innovative and targeted ways to educate and involve them in end-of-life decision-
making and care planning.   
 Next, in the integrative review of end-of-life experiences and processes for 
providers, families, and patients with an LVAD, I identified a dearth of research in the 
area. The six articles that were identified, illuminated that patients and caregivers are 
unprepared to make the necessary decisions regarding deactivation at the end-of-life, and 
are left frustrated and confused at these times. Providers in multiple fields, including 
cardiology, palliative medicine, and cardiothoracic surgery, all have differing opinions on 
how to handle end-of-life scenarios for patients with an LVAD, and are unsure of the 
ethical permissibility of deactivation. This limited evidence highlights the need to 
develop a more comprehensive understanding of what patients are being told about end-
of-life with an LVAD, and how providers’ opinions are related to when these discussions 




related to end-of-life experiences and attitudes for patients with an LVAD reported in 
Chapter Five.  
 In order to ensure there was an adequate measure of perceived control in the 
LVAD population, the findings in Chapter Four established that using the CAS-R in the 
LVAD population is a valid and reliable measurement of perceived control. This could 
aide future studies to identify the role perceived control plays in end-of-life decision-
making and is also a modifiable trait that could be targeted in interventions to promote 
informed decision-making.  
 Findings in Chapter Five were the first exploration and description of end-of-life 
attitudes and experiences related to end-of-life deactivation and pump exchange of 
patients with an LVAD. These findings demonstrated, similar to those found in the ICD 
study, that there are significant portions of the population who have never discussed any 
scenarios related to end-of-life with their providers. There are also a large percentage of 
the population, despite the high risks associated with living with an LVAD, who would 
choose to never have a conversation related to end-of-life decision making. Unlike in the 
ICD study, we were unable to isolate specific factors that predicted having an end-of-life 
discussion with their provider or next-of-kin regarding end-of-life, and further research is 
needed to continue to understand these phenomena.  
 Finally, through all the findings from this dissertation, I am beginning to assemble 
the foundations of a conceptual model aimed at identifying factors associated with end-
of-life decision making for patients with a cardiac device. By beginning to identify 
specific factors such as ICD shock history, and high levels of concern and anxiety, 




higher rates of end-of-life discussions. Through the integrative review, we can see that 
lack of education and guidance to patients, families, and providers result in disjointed and 
poor end-of-life setting for all shareholders involved. By having a validated tool to 
measure a possible factor involved in end-of-life decision making, as seen in the CAS-R 
testing, we can begin to test perceived control as a possible target in end-of-life decision 
making framework. And lastly, by examining the experiences and attitudes related to 
end-of-life decision-making in the LVAD population, we can start to analyze various 
factors that this unique population all needs addressed in their decision-making process. 
Also, in the LVAD end-of-life study, we aimed to identify the role that cognition may 
play in end-of-life decision making, and while in this study, it did not impact decision-
making, more research in the future is needed to clearly identify the role that cognition 
plays in these complicated processes. Through these studies, an outline of a framework 
can begin to be deciphered and more thoroughly tested in the future.  
6.4 Recommendations for Practice and Research  
 End-of-life decision making is an over-looked component of care for patients with 
a cardiac device. In multiple studies, evidence has shown that patients with cardiac 
devices are not informed about the decisions that should be made prior to end-of-life 
scenarios, which could ultimately end up harming the patient. Future studies should 
continue to examine the experiences of patients and their families regarding the 
experiences related to end-of-life situations they are experiencing, especially in the 
LVAD community. I hope to continue the study described in Chapter Five at other 





 Another large gap in the current literature and practice is what providers are being 
taught and what are they experiencing when trying to discuss end-of-life scenarios with 
their patients. In two populations of patients who have cardiac devices, and both 
demonstrated that 40% had never discussed end-of-life scenarios with their providers. It 
is critical to understand what may deter providers from discussing end-of-life with certain 
patients, or if there is a disconnect where providers feel they have discussed a concept 
adequately, but in fact the patient does not feel the issue has been discussed. In discussing 
this phenomenon with another LVAD researcher, Colleen McIlvennan, DNP, RN, she 
also agrees that more research is needed on provider education about end-of-life 
discussions, and she is currently in the grant-submission process on a study within this 
area.  
 Additional studies are also needed in the area related to reaching people who do 
not want to discuss end-of-life decision making. In both the LVAD and ICD study, 
around 40% said they never wished to have a discussion with their provider regarding 
deactivation or end-of-life. It would prudent to qualitatively evaluate these types of 
patients to see what their concerns related to this topic are and how healthcare providers 
and researchers can more adequately meet their needs, increase their comfort surrounding 
these types of conversations, and ensure they have the tools they need to make decisions 
for end-of-life care.  
 Last, over the course of my career I hope to continue to build on the conceptual 
model around decision-making at the end-of-life. By continuing to identify factors 
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